

### THE UNIVERSITY of EDINBURGH

### Edinburgh Research Explorer

### Codon Usage and Splicing Jointly Influence mRNA Localization

#### Citation for published version:

Mordstein, C, Savisaar, R, Young, RS, Bazile, J, Talmane, L, Luft, J, Liss, M, Taylor, MS, Hurst, LD & Kudla, G 2020, 'Codon Usage and Splicing Jointly Influence mRNA Localization', *Cell Systems*, vol. 10, no. 4, pp. 351-362.e8. https://doi.org/10.1016/j.cels.2020.03.001

#### **Digital Object Identifier (DOI):**

10.1016/j.cels.2020.03.001

Link: Link to publication record in Edinburgh Research Explorer

**Document Version:** Peer reviewed version

**Published In: Cell Systems** 

#### **General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



# Codon usage and splicing jointly influence mRNA localization

Christine Mordstein<sup>1,2</sup>, Rosina Savisaar<sup>2,3</sup>, Robert S Young<sup>1,4</sup>, Jeanne Bazile<sup>1</sup>, Lana Talmane<sup>1</sup>, Juliet Luft<sup>1</sup>, Michael Liss<sup>5</sup>, Martin S Taylor<sup>1</sup>, Laurence D Hurst<sup>2</sup>, Grzegorz Kudla<sup>1\*</sup>

<sup>1</sup>MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK

<sup>2</sup>Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK

<sup>3</sup>Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

<sup>4</sup>Centre for Global Health Research, Usher Institute, The University of Edinburgh, Edinburgh, UK

<sup>5</sup>Thermo Fisher Scientific, GENEART GmbH, Regensburg, Germany

\*Lead Contact (Corresponding Author): Grzegorz Kudla (gkudla@gmail.com)

#### 1 Abstract

2

3 In the human genome, most genes undergo splicing and patterns of codon usage 4 are splicing-dependent: guanine and cytosine (GC) content is highest within 5 single-exon genes and within first exons of multi-exon genes. However, the 6 effects of codon usage on gene expression are typically characterized in 7 unspliced model genes. Here, we measured the effects of splicing on expression 8 in a panel of synonymous reporter genes that varied in nucleotide composition. 9 We found that high GC content increased protein yield, mRNA yield, cytoplasmic 10 mRNA localization and translation of unspliced reporters. Splicing did not affect 11 the expression of GC-rich variants. However, splicing promoted the expression 12 of AT-rich variants by increasing their steady-state protein and mRNA levels, in 13 part through promoting cytoplasmic localization of mRNA. We propose that 14 splicing promotes the nuclear export of AU-rich mRNAs and that codon- and 15 splicing-dependent effects on expression are under evolutionary pressure in the 16 human genome.

#### 18 Introduction

19

20 Mammalian genomes are characterised by large regional variation in base 21 composition (Bernardi, 1993). Regions with a high density of G and C nucleotides 22 (GC-rich regions) are in an open, transcriptionally active state, are gene-dense, 23 and replicate early. In contrast, AT-rich regions are enriched with 24 heterochromatin, contain large gene deserts and replicate late (Arhondakis et al., 25 2011; Lander et al., 2001; Vinogradov, 2003). The mechanisms that give rise to 26 this compositional heterogeneity have been under debate for years and many 27 researchers believe that the pattern originates from the process of GC-biased 28 gene conversion (Duret and Galtier, 2009), though other neutral and selective 29 mechanisms have been proposed as well (Eyre-Walker, 1991; Galtier et al., 2018; 30 Plotkin and Kudla, 2011; Sharp and Li, 1987b).

31

32 The sequence composition of mammalian genes correlates with the GC-content 33 of their genomic location. Thus, introns and exons of genes located in GC-rich 34 parts of the genome are themselves GC-rich. This can potentially influence gene 35 expression in multiple ways: nucleotide composition affects the physical 36 properties of DNA, the thermodynamic stability of RNA folding, the propensity of 37 RNA to interact with other RNAs and proteins, the codon adaptation of mRNA to 38 tRNA pools, and the propensity for RNA modifications, such as m6A (Dominissini 39 et al., 2012) and ac4C (Arango et al., 2018). However, studies of the effects of 40 nucleotide composition on gene expression in human cells have led to opposing 41 conclusions. On the one hand, heterologous expression experiments typically 42 report large positive effects of increased GC content on protein production in a 43 wide variety of transgenes, including fluorescent reporter genes, human cDNAs, 44 and virus genes (Bauer et al., 2010; Kosovac et al., 2011; Kotsopoulou et al., 45 2000; Kudla et al., 2006; Zolotukhin et al., 1996). As a result, increasing the GC 46 content of transgenes has become a common strategy in coding sequence optimization for heterologous expression in human cells (Fath et al., 2011). On 47 the other hand, genome-wide analyses of endogenous genes typically show little 48 49 or no correlation of GC content with expression (Duan et al., 2013; Lercher et al., 50 2003; Rudolph et al., 2016; Semon et al., 2005).

51

52 We hypothesized that the conflicting results in heterologous and endogenous 53 gene expression studies might be explained by RNA splicing. Most transgenes 54 used in heterologous expression systems have no introns, whereas 97% of genes 55 in the human genome contain one or more introns. Splicing is known to influence 56 gene expression at multiple stages, including nuclear RNP assembly, RNA export, 57 and translation. If splicing selectively increased the expression of AT-rich genes, 58 it could account for the lack of correlation of GC content and gene expression in 59 previous genome-wide studies. We therefore compared spliced and unspliced genes with respect to their (1) genomic codon usage, (2) expression levels of 60 61 reporter genes in transient and stable transfection experiments and (3) global 62 expression patterns in human transcriptome studies. We show that splicing 63 increases the expression of AT-rich genes, but not GC-rich genes, in part through 64 effects on cytoplasmic RNA enrichment.

65

#### 66 Results

67

#### 68 **Codon usage of human protein-coding genes depends on RNA splicing**

69 We first analysed the relationship between the nucleotide composition of human 70 genes and splicing. GC4 content (guanine and cytosine content at 4-fold 71 degenerate sites of codons) correlates negatively with the number of exons in 72 humans (Figure 1A; Spearman's  $\rho = -0.27$ ; p < 2.2×10<sup>-16</sup>; see also (Carels and 73 Bernardi, 2000; Ressayre et al., 2015; Savisaar and Hurst, 2016)). In addition, 74 GC4 content is highest in 5'-proximal exons (Figure 1B; Spearman's  $\rho = -0.18$ ; p  $< 2.2 \times 10^{-16}$ ), and first exons have a higher GC4 content than second exons (p < 75 76 2.2×10<sup>-16</sup>, one-tailed Wilcoxon test). Although these patterns could result from 77 proximity to GC-rich transcription start sites (TSSs) (Zhang et al., 2004), we 78 found that first exons have significantly higher GC4 content than second exons 79 even when controlling for the distance from the TSS (Figure 1C). This suggests 80 that splicing contributes to the observed enrichment of G and C nucleotides in 81 the 5'-proximal exons in humans. Interestingly, there is little association 82 between exon counts and GC content among human lncRNAs (Figure S1).

84 To understand the causal links between splicing and nucleotide composition, we 85 studied the compositional patterns of retrogenes. Retrotransposition provides a 86 natural evolutionary experiment of what happens when a previously spliced 87 gene suddenly loses its introns. We first analysed a set of 49 parent-retrogene 88 pairs for which both the parent and the retrocopy ORFs have been retained in 89 human and mouse. We found that the retrocopies had a significantly higher GC4 90 content than their parents (median GC4<sub>retrocopy</sub> - GC4<sub>parent</sub> = 11.5%; p =  $2.1 \times 10^{-4}$ 91 from one-tailed Wilcoxon test; Figure 1D). It thus appears that after 92 retrotransposition, newly integrated intronless genes come under selective 93 pressure for increased GC content. In a comparison of 31 parent-retrogene pairs 94 retained between human and macaque, the median GC4 difference is not 95 significant (0.09%; p = 0.13, Wilcoxon test), but this may be explained by duplication events in macaques being more recent (dS  $\sim$  0.08) than in mouse (dS 96 97  $\sim$  0.56) (Gradnigo et al., 2016; Ponting and Goodstadt, 2009) so that changes in 98 GC composition might not have had time to accumulate. As a control, we 99 analysed retrocopies classified as pseudogenes (Figure S1D) and found their GC4 100 content to be significantly lower compared to their parental genes (-2.9%; p < 101 2.2×10<sup>-16</sup>, Wilcoxon test). Furthermore, the genomic neighbourhood of 102 functional retrocopies and pseudogenes had significantly lower GC content than 103 the neighbourhood of their respective parental genes (Figure S1E), suggesting 104 that increased GC content is not intrinsically connected with retrotransposition, 105 but is required for maintaining long-term functionality of retrogenes. Taken 106 together, these results support a splicing-dependent mechanism shaping 107 conserved patterns of nucleotide composition across functional protein-coding 108 genes.

109

#### 110 **GC-content is a strong predictor of expression of unspliced reporter genes**

111 The above analyses show a connection between splicing and genomic GC content 112 of endogenous human genes. To test whether splicing differentially affects the 113 expression of genes depending on their GC content, we designed 22 synonymous 114 variants of GFP that span a broad range of GC3 content (GC content at the third 115 positions of codons) (Mittal et al., 2018) (Figure S2). The collection encompasses 116 most of the variation in GC3 content found among human genes. All variants 117 were independently designed by randomly drawing each codon from an 118 appropriate probability distribution, to ensure uniform GC content and statistical 119 independence between sequences. We cloned these variants into two 120 mammalian expression vectors: an intronless vector with a CMV promoter 121 (pCM3) and a version of the same vector with a synthetic intron located in the 5' 122 UTR (pCM4). The GC content profiles of the 5' UTRs were similar in both vectors 123 (Figure S2E,F), and the intron was spliced efficiently in all variants tested, 124 independently of the coding sequence GC content (Figure S3A). The vectors also 125 encoded a far-red fluorescent protein, mKate2, which we used to normalize GFP 126 protein abundance (normalization reduced measurement noise, but similar 127 results were obtained with and without normalization). Transient transfections 128 of HeLa cells with three independent preparations of each plasmid showed 129 reproducible expression with a large dynamic range: synonymous variants 130 differed in GFP protein production 46-fold. Consistent with previous studies, GFP 131 fluorescence was strongly correlated with GC3 content in unspliced genes (Figure 2A). Introduction of an intron into the 5' UTR increased the expression of 132 133 most, but not all variants. Typically, GC-poor variants experienced a large 134 increase of expression in the presence of an intron, whereas GC-rich variants 135 were unaffected or experienced a moderate increase (Figure 2B,C).

136

137 We obtained similar results in stably transfected HEK293 and HeLa cells (Figure 138 S3B,C) and when expressing an independently designed collection of 25 139 synonymous variants of mKate2 in HeLa cells (Figure 2D-F). A Fisher's exact test 140 revealed that the expression of GC-poor variants was more likely to be increased 141 by splicing, compared to GC-rich variants (GC3<60% vs GC3>60%, p=0.02, N=47, 142 GFP and mKate variants combined). These experiments show that many AT-rich 143 genetic variants are expressed inefficiently in human cells, but low expression 144 can be partially rescued by splicing. Notably, the average GC content of the 145 human genome is 41% (Li, 2011). In our experiments, genes with GC content at 146 or below 41% are expressed extremely inefficiently, unless they contain an 147 intron (Figure 2A,B). This may provide a strong selective pressure for 148 maintaining introns in human genes.

150 To establish which stages of expression are responsible for these observations, 151 we first measured mRNA abundance of GFP variants in transiently transfected 152 HeLa cells by quantitative RT-PCR (qRT-PCR). High GC content may introduce 153 unwanted bias in PCR, so to allow fair comparison of all variants irrespective of 154 their GC content, PCR primers were placed in the untranslated regions, whose 155 sequence did not vary. Similar to protein levels, mRNA abundance varied widely 156 between synonymous variants of GFP. GC-poor variants experienced a large 157 increase of expression in the presence of an intron, whereas GC-rich variants 158 were less affected (Figure 2G-I). The range of variation in mRNA abundance was 159 much smaller in constructs with an intron than without intron (Figure 2I), 160 indicating that splicing compensates the effects of GC content on expression.

161

162 We then asked if changes in mRNA abundance arose at transcriptional or post-163 transcriptional levels. As a proxy for transcriptional efficiency, we measured the 164 abundance of intronic RNA for GFP variants expressed from the introncontaining plasmid. Coding sequence GC content did not correlate with intronic 165 166 RNA abundance (Figure 2]), suggesting that transcription of the 5' UTR intron 167 does not depend on GC content of the coding sequence. We further performed 168 metabolic labelling of nascent RNA using 4-thiouridine (4sU) in cell lines stably 169 expressing GC-poor and GC-rich GFP variants, expressed both with and without 170 5' UTR intron, followed by nascent RNA purification and qRT-PCR (Figure 171 S3D,E). We did not observe any systematic variation in nascent GFP RNA levels 172 that could be explained by either GC content or splicing. Conversely, high GC 173 content was associated with stabilization in unspliced and spliced constructs 174 (Figure 2K). Taken together, these experiments show that high GC content 175 enhances gene expression at a post-transcriptional level, and that the effect of GC 176 content on expression is modulated by splicing.

177

#### 178 High GC content at the 5' end correlates with efficient expression

To further explore the sequence determinants of expression, we assembled a pool of 217 synonymous variants of GFP that included the 22 variants studied above, 137 variants from our earlier study (Kudla et al., 2009), and 58 additional variants. We cloned the collection into plasmids with and without a 5' UTR

183 intron. We then established pools of HeLa Flp-In T-REx cells that stably express 184 these constructs from a single genomic locus under a doxycycline-inducible promoter and measured the protein levels of all variants by Flow-Seq (Kosuri et 185 186 al., 2013). We also performed Flow-Seq in HEK293 cells using the intronless constructs only. In Flow-Seq, a pool of cells is sorted by FACS into bins of 187 188 increasing fluorescence and the distribution of variants in each bin is probed by 189 amplicon sequencing to quantify protein abundance (Figure 3A). All variants 190 could be quantified with good technical and biological reproducibility, and high 191 correlation was found between Flow-Seq and spectrofluorometric measurement 192 of individual constructs (Figure S4). Most variants showed the expected 193 unimodal distribution across fluorescence bins, but some variants showed 194 bimodal distributions, possibly indicative of gene silencing in a fraction of cells.

195

196 All Flow-Seg experiments showed substantial variation of expression between 197 synonymous variants of GFP (Figure 3B). GFP protein levels in HeLa cells (with intron), HeLa cells (without intron), and HEK293 cells (without intron) were all 198 199 correlated with each other, but the moderate degree of correlation (r=0.51 200 HEK293 (without intron) vs HeLa (without intron); r=0.36 Hela (with intron) vs 201 HeLa (without intron)) suggests that the effects of codon usage on expression 202 are modulated by splicing and by cell line identity - in agreement with prior 203 observations of tissue-specific codon usage (Burow et al., 2018; Gingold et al., 204 2014; Plotkin et al., 2004; Rudolph et al., 2016). Flow-Seq confirms the positive 205 correlation of synonymous site GC-content with expression of unspliced variants, 206 whereas no significant correlation was found among intron-containing variants 207 (Figure 3C). In contrast to results reported by us and others in bacteria and yeast 208 (Cambray et al., 2018; Goodman et al., 2013; Kudla et al., 2009; Shah et al., 2013), 209 but consistently with the positive correlation between GC content and 210 expression, strong mRNA folding near the beginning of the coding sequence 211 correlated with increased expression (Spearman's  $\rho = 0.27$  in HeLa cells;  $\rho = 0.4$ 212 in HEK293 cells). Expression was positively correlated with CpG content and 213 codon adaptation index (CAI), and negatively correlated with the estimated 214 density of AU-rich elements (ARE) or cryptic splice sites (see STAR methods for 215 definitions of all sequence features tested). Because of the strong correlation

between GC content, CpG content, CAI and mRNA folding energy, a multiple
regression analysis could not resolve which of these properties was causally
related to expression.

219

220 Some of the variants analysed by Flow-Seq featured large regional variation in 221 GC content (Figure S5A) and we asked whether the localization of low-GC and 222 high-GC regions within the coding sequence influences expression. We found 223 that the GC3 content in the first half of the coding sequence (nt 1-360), but not in 224 the second half (nt 361-720), was positively correlated with expression of 225 intronless GFP variants in the HeLa and HEK293 cells (Figure 3D). The GC3 226 content in either half of the gene showed no correlation with expression in the 227 intron-containing constructs.

228

229 To further test whether GC content at the 5' end of genes has a particularly 230 important effect on expression, we constructed in-frame fusions between GCrich and GC-poor variants of GFP and mKate2 genes and quantified their protein 231 232 and mRNA abundance in transient transfection experiments. RNA and protein 233 yields showed a dependence on the GC content profile: GC-poor mKate2 showed 234 nearly undetectable expression on its own, or when fused to the 5' end of GC-rich 235 GFP, but it was efficiently expressed when fused to the 3' end of GC-rich GFP 236 (Figure 3E, left panels). Similarly, expression of GC-poor GFP was significantly 237 enhanced when it was fused to the 3' end of GC-rich mKate2 (Figure 3E, right 238 panels). By contrast, pairs of GC-rich variants were efficiently expressed when 239 fused in either orientation. N-terminal fusion of GC-rich GFP had a slightly larger 240 positive effect on expression compared to GC-rich mKate, perhaps because of 241 differences in codon usage or protein folding. Taken together, these experiments 242 confirm that GC content near the 5' end of the coding sequence has a large effect 243 on expression.

244

#### 245 Introns within the coding sequence enhance GC-poor gene expression

While the experiments described above utilised an intron placed in the 5' UTR, itshould be noted that most introns within human genes are found within the CDS.

- 248 To examine the relationship between intron location and gene expression
  - 9

249 changes relating to codon usage, we modified two GFP variants by moving their 250 introns from the 5' UTR into the coding sequence (Figure 3F). We chose variants 251 that were AT-rich (GC3=0.38 and 0.37), poorly expressed (HeLa Flow-Seq scores 252 3.71 and 4.4.) and experienced a large increase in expression when expressed 253 with a 5' UTR intron (HeLa Flow-seq scores 6.18 and 5.98). Transient 254 transfections confirmed the positive effect of a 5' UTR intron on expression of 255 both variants (Figure 3F, first 2 bars in each plot). When the intron was placed 256 within the coding sequence, expression was also increased compared to the 257 intronless counterparts, suggesting that the positive effects of splicing on 258 expression are not inherently linked to the intron position. For one of the 259 variants, the inclusion of both 5' UTR and CDS introns led to a further increase in 260 expression. This is consistent with our genome-wide observation that codon 261 usage is linked to number of introns. Taken together, these results support a 262 splicing-dependent effect of codon usage on gene expression.

263

## High GC content leads to cytoplasmic enrichment of mRNA and higher ribosome association

266 We then used the pooled HeLa cell lines to analyse the effects of GC content on 267 mRNA localization. We separated the cells into nuclear and cytoplasmic 268 fractions, isolated RNA and performed amplicon sequencing of each fraction to 269 analyse mRNA localization of each GFP variant. Analysis of fractions showed the 270 expected enrichment of the lncRNA MALAT1 in the nucleus, and of tRNA in the 271 cytoplasm, confirming the quality of fractionations (Figure 4A). For each GFP 272 variant, we calculated the relative cytoplasmic concentration of its mRNA (RCC) 273 as the ratio of cytoplasmic read counts to the sum of reads from both fractions 274 (RCC = c\_cyto / (c\_cyto+c\_nuc); Figure 4B). A value of 0 therefore indicates 100% 275 nuclear retention, whereas a value of 1 indicates 100% cytoplasmic localization. 276 In the absence of splicing, RCC scores ranged from 0.09 to 0.64 and RCC correlated significantly with GC content (r=0.51, p= $3.85 \times 10^{-13}$ , Figure 4C). In the 277 278 presence of a 5' UTR intron, we observed a significant increase in RCC score for 279 GFP variants with low GC content, but no increase in RCC for GC-rich variants 280 (Figure 4D). GC3 content at the beginning of the coding sequence was 281 significantly correlated with RCC in the absence of splicing (r=0.5, p= $2.0 \times 10^{-11}$ ),

but not in the presence of splicing (r<0.01, p=0.48; Figure S5B). Thus, high GC</li>
content at the 5' end of genes increases gene expression in part through
facilitating the cytoplasmic localization of mRNA.

285

286 To assess whether GC content also affects translational dynamics, we performed 287 polysome profiling on HEK293 GFP pool cells using sucrose gradient 288 fractionation (Figure 5A). qRT-PCR analysis of RNA extracted from all collected 289 fractions showed a broad distribution of GFP across fractions, with enrichment 290 within polysome-associated fractions. In order to determine distribution patterns of individual GFP variants, RNA from several fractions was pooled (as 291 292 indicated in Figure 5B) and subjected to high-throughput sequencing. The 293 resulting read distribution indicates that GC-rich variants are associated with 294 denser polysomal fractions (ribosome density, Figure 5C, left panel; R<sup>2</sup>=0.55, p < 295  $2.2 \times 10^{-16}$ ) and are more likely to be translated (ribosome association, Figure 5C, 296 right panel; R<sup>2</sup>=0.28, p<9.03×10<sup>-15</sup>), compared to GC-poor variants. This suggests 297 that enhanced translational dynamics also contribute to more efficient 298 expression of GC-rich genes.

299

# The expression fate of endogenous RNA depends on splicing, nucleotide composition, and cell type

302 To test whether splicing- and position-dependent effects of codon usage can be 303 observed among human genes, we turned to genome-wide measurements of 304 expression at endogenous human loci and related these measurements to codon 305 usage and splicing. Although the correlations between GC content and 306 expression depended on the experimental measure and type of cells under study, 307 we find that GC4 content usually has a more positive effect on gene expression in unspliced genes relative to spliced ones (Figure 6, Table S1). In particular, 308 309 unspliced mRNAs show a more positive/less negative correlation of GC4 with 310 transcription initiation (GRO-cap data); cytoplasmic stability (exosome mutant); 311 RNA (whole cell RNA-seq); cytoplasmic enrichment (cell fractionation), 312 translation rate (ribosome profiling vs whole cell RNA-seq); and protein amount 313 (mass-spec). These analyses suggest that GC4 content has an effect on the RNA 314 abundance of intronless mRNA molecules, which is carried through to the protein expression. Taken together, these genome-wide analyses support our
observation of a splicing-dependent relationship between codon usage and
expression in human cells.

318

#### 319 Discussion

320

321 We have shown that the effects of GC content on gene expression in human cells 322 are splicing-dependent (the effect is larger in unspliced genes compared to 323 spliced genes) and position-dependent (the effect is larger at the 5' end of genes 324 than at the 3' end). In addition, human genes show striking patterns of codon 325 usage, which differ between spliced and unspliced genes and between first and 326 subsequent exons. Our results have implications for the understanding of the 327 evolution of human genes and the functional consequences of synonymous 328 codon usage.

329

#### 330 Mechanisms of splicing- and position-dependent effects of codon usage

331 Specific patterns of codon usage have previously been found at the 5' ends of 332 genes in bacteria, yeast and other species (Gu et al., 2010; Kudla et al., 2009; 333 Tuller et al., 2010). In bacteria and yeast, strong mRNA folding near the start 334 codon prevents ribosome binding and reduces translation efficiency, resulting in 335 selection against strongly folded 5' mRNA regions (Kudla et al., 2009; Shah et al., 2013). In addition a "ramp" of rare codons has been observed near the 5' end of 336 337 RNAs in multiple species, with a possible role in preventing a wasteful 338 accumulation of ribosomes on mRNAs (Tuller et al., 2010) or reducing the 339 strength of mRNA folding (Bentele et al., 2013). These phenomena cannot 340 explain our results in human, because both the folding energy and codon ramp 341 models predict low GC content near the start codon, whereas we observe high GC 342 content within first exons of human protein-coding genes (Figure 1B). 343 Furthermore, our experiments show that high GC content near the start codon increases expression, whereas the folding energy and codon ramp models would 344 345 predict low expression.

346

347 We propose instead that splicing- and position-dependent effects of GC content 348 are explained by early post-transcriptional events in the lifetime of an mRNA. 349 Using matched reporter gene libraries, we show that most, but not all, variants 350 show an increase in expression when spliced. Splicing typically increases the 351 expression of AT-rich variants, but it does not further increase the expression of 352 GC-rich transcripts, which suggests that splicing and high GC content influence 353 expression through at least one common mechanism. Splicing increases 354 transcription (Kwek et al., 2002), prevents nuclear degradation (Nott et al., 355 2003), facilitates nuclear-cytoplasmic mRNA export through the Aly/REF-TREX 356 pathway (Muller-McNicoll et al., 2016), and stimulates translation (Nott et al., 357 2004). High GC content might increase RNA polymerase processivity (Bauer et 358 al., 2010; Zhou et al., 2016); AT-rich genes are more likely to contain cryptic 359 polyadenvlation sites (consensus sequence: AAUAAA) (Higgs et al., 1983; Zhou et 360 al., 2018) or destabilizing AU-Rich Elements (AREs); and AU-rich mRNAs may be 361 preferentially localized in P-bodies (Courel et al., 2019) or in the nucleus (this study). GC-rich sequence elements of endogenous unspliced genes were 362 363 previously shown to route transcripts into the splicing-independent ALREX 364 nuclear export pathway, allowing efficient cytoplasmic accumulation (Palazzo et 365 al., 2007). In agreement with this, low expression caused by inhibitory sequence 366 features (such as low GC-content) can be rescued by extending the mRNA at the 367 5'end with a GC-rich sequence (Figure 3E). This may act as a compensatory mechanism when gene expression cannot rely on the positive regulatory effects 368 369 of splicing (Palazzo and Akef, 2012). In contrast, it was recently shown that 370 binding of HNRNPK to the GC-rich SIRLOIN motif leads to nuclear enrichment of 371 IncRNAs (and also some mRNAs) (Lubelsky and Ulitsky, 2018). Our genomic 372 analyses of lncRNA sequences do not show the same splicing-dependent 373 compositional patterns as observed in mRNAs and it is therefore likely that 374 antagonistic pathways act simultaneously in shaping the RNA expression 375 landscape. Thus, we propose that the genomic patterns and their consequences 376 on gene expression reported here are general features of protein-coding genes.

377

Recent studies highlight patterns of codon usage as major determinants of RNA
stability in yeast (Presnyak et al., 2015), zebrafish (Mishima and Tomari, 2016)

380 and other species (Bazzini et al., 2016). The usage of less common, 'non-optimal' 381 codons within transcripts was shown to control poly-A tail length and RNA half-382 life in a translation-dependent manner through the coupled activity of different CCR4-NOT nucleases (Radhakrishnan et al., 2016; Webster et al., 2018). 383 384 Consistent with these findings, we observed that CAI is positively correlated with 385 mRNA expression levels in human cells. However, it remains to be seen whether 386 the correlation of CAI with mRNA expression depends on translation. Because of 387 the strong correlation between GC content and CAI, it is difficult to disentangle 388 independent contributions of these variables. Additionally, we find that the 389 correlation between GC content (or CAI) and expression is position- and splicing-390 dependent, whereas no evidence for such context-dependence has been reported 391 for the CCR4-NOT-mediated mechanism.

392

393 Other instances in which the effects of codon usage are context-dependent have 394 been described. Most notably, tRNA populations and transcriptome codon usage 395 patterns were shown to differ between mammalian tissues (Dittmar et al., 2006; 396 Gingold et al., 2014; Plotkin et al., 2004; Rudolph et al., 2016). Intriguingly, genes 397 preferentially expressed in proliferating cells and tissue-specific genes tend to be AT-rich, whereas genes expressed in differentiated cell types and housekeeping 398 399 genes are more GC-rich (Gingold et al., 2014; Vinogradov, 2003). Although these 400 differences have been interpreted in terms of the match between codon usage 401 and cellular tRNA pools, it is plausible that translation-independent mechanisms 402 contribute to context-dependent effects of codon usage. Accordingly, in 403 Drosophila, codon optimality determines mRNA stability in whole cell embryos, 404 but not in the nervous system, independent of tRNA abundance (Burow et al., 405 2018). Recently, it was shown that Zinc-finger Antiviral Protein (ZAP) selectively 406 recognises high CpG-containing viral transcripts as a mechanism to distinguish 407 self from non-self (Takata et al., 2017). We speculate that similar regulatory 408 proteins and mechanisms exist for cellular expressed genes. The cell lines used 409 in the present study, HeLa and HEK293, are both rapidly proliferating and 410 experimental results are correlated (r=0.36, Flow-Seq data), but divergent 411 expression of some GFP variants was also observed. Similarly, the effect size of 412 GC content on the expression of endogenously expressed genes varies with cell

413 type. It would be interesting to compare the expression of our variants in other
414 cell types to further address the question of tissue-specific codon usage and
415 adaptation to tRNA pools.

416

#### 417 Implications for the evolution of protein-coding genes

418 The fact that long, multi-exon genes are often found in GC-poor regions of the 419 genome might result from regional mutation bias, but an alternative explanation 420 is possible: GC-poor genes may be under selective pressure to retain their 421 introns, and intronless genes may experience selective pressure to increase their 422 GC content. These alternative explanations are supported by multiple 423 observations: Firstly, endogenous intronless genes are on average more GC-rich 424 than intron-containing genes. Secondly, the GC content of functional (but not 425 non-functional) retrogenes is higher compared to their respective introncontaining parental genes, which cannot be explained by a systematic integration 426 427 bias. Thirdly, in genome-wide analysis, correlations between GC-content and expression are generally more positive (or less negative) for unspliced compared 428 429 to spliced genes. Taken together, this suggests that for the long-term success of 430 an unspliced gene (i.e. stable conservation of expression and functionality) an 431 increase in GC content is essential. By contrast, splicing allows genes to remain 432 functional even when mutation bias or other mechanisms lead to a decrease of 433 their GC content.

#### 434 Acknowledgments

435 We thank Elisabeth Freyer from the IGMM FACS facility for help with cell sorting; 436 Andrew Jackson, Nick Gilbert and Aleksandra Helwak for gifts of cell lines and 437 plasmids; James Brindle for technical assistance; members of Kudla and Hurst 438 groups for discussions; Edinburgh Genomics (University of Edinburgh) and the 439 Imperial BRC Genomics facility for next-generation sequencing; and the IGMM 440 technical support facility for help with media preparation and sequencing. This 441 work was supported by the Wellcome Trust (Fellowships 097383 and 207507 to 442 GK), the European Research Council (Advanced grant ERC-2014-ADG 669207 to 443 LDH), the Medical Research Council (Grants MC\_UU\_00007/11 to MST. and 444 MC\_UU\_00007/12 to GK and PhD studentship to CM), and Thermofisher (Cross 445 Collaboration Grant to ML and GK).

446

#### 447 Author Contributions

CM and GK conceived the work and designed experiments. CM and JB performed
experiments. ML provided reagents and analysis tools. CM, RS, RSY, LT, JL and GK
analysed data. ML, MST and LDH provided expertise and feedback. CM and GK
wrote the paper.

452

#### 453 **Declaration of Interests**

- 454 The authors declare no competing interests.
- 455

## 456 Figure 1. Splicing- and position-dependent patterns of nucleotide 457 composition in human genes.

- (A) GC4 distribution of human protein-coding genes, grouped by number of
  exons per gene. The Y axis indicates the proportion of genes within a given range
  of GC4.
- 461 (B) Mean GC4 content in protein-coding exons, grouped by exon position (rank)
- and by number of exons per gene.
- 463 (C) Mean GC4 for individual codons within exons of rank 1 (black dots) or rank 2
- 464 (white dots) downstream of the transcription start site (TSS).
- 465 (D) GC4 distribution of functional retrogenes (dark grey) and their466 corresponding parental genes (light grey) conserved between mouse and human

467  $(p=2.1\times10^{-4})$ , from one-tailed Wilcoxon signed rank test, n=49). See also Figure 468 S1.

469

#### 470 Figure 2. The effect of GC content on gene expression depends on splicing.

471 (A-B) Protein levels of 22 GFP variants when transiently expressed as unspliced 472 (A) or spliced (B) constructs in HeLa cells and quantified by spectrofluorometry. 473 Each data point represents the mean of 9 replicates, +/- SEM. GFP Relative 474 Fluorescence Units (RFU) are defined as (GFP fluorescence - background GFP 475 fluorescence)/(mKate fluorescence - background mKate fluorescence), where 476 background fluorescence was measured in mock-transfected cells.

477 (C) Correlation of protein levels between unspliced and spliced variants of GFP 478

 $(n=22, R^2=0.69, p=9.0\times 10^{-7})$ . The dashed line indicates x=y.

479 (D-E) Protein levels of 23 mKate2 variants in the absence (D) or presence (E) of

480 splicing. Each data point represents the mean of 9 replicates, +/- SEM. mKate

481 RFU are defined as (mKate fluorescence - background mKate fluorescence), 482 where background fluorescence was measured in mock-transfected cells.

483 (F) Correlation of protein levels between unspliced and spliced variants of mKate2 (n=23, R<sup>2</sup>=0.29, p=2.8×10<sup>-4</sup>). 484

485 (G-H) mRNA levels of 10 GFP variants when transiently expressed as unspliced 486 (G) or spliced (H) constructs in HeLa cells and quantified by qRT-PCR. Data points represent the mean of 3 replicates, +/- SEM, calculated as (GFP 487 488 RNA)/(NeoR RNA).

489 (I) Comparison of mRNA expression from spliced and unspliced GFP variants 490  $(n=10, R^2=0.49, p=0.014).$ 

491 (J) Intronic RNA levels of GFP variants measured by qRT-PCR, calculated as (GFP 492 intronic RNA)/(NeoR RNA).

493 (K) RNA stability time course of 6 GFP variants expressed from stably 494 transfected HEK293 Flp-in cells after blocking transcription with 500 nM 495 triptolide. Variants were expressed as unspliced and spliced constructs. Results 496 represent the averages of 2 independent experiments. RNA stability of c-myc 497 (n=12) and GAPDH (n=6) are shown as unstable and stable RNA controls. See 498 also Figures S2 and S3.

Figure 3. Splicing- and position-dependent effects of codon usage on
protein production.

502 (A) Schematic outline of Flow-Seq experimental workflow. Stable HeLa and
503 HEK293 cell pools expressing 217 GFP variants were established using a
504 multiplex Flp-In integration approach, followed by FACS sorting, sequencing and
505 calculation of a fluorescence score for each variant (see Figure S4).

(B) Heatmap representation of Flow-Seq results. Rows represent normalised
read distributions of individual GFP variants across 8 fluorescence bins
(columns). The average difference between lowest and highest fluorescence bins
is around 100-fold. Data shown represents the average of 3 Flow-Seq
measurements for HeLa cells, the average of 2 Flow-Seq experiments for HeLa
with intron and 1 experiment for HEK293 cells.

512 (C) Pearson correlation matrix of experimental measurements obtained by Flow-513 Seq and sequence covariates. The colour of squares indicates the correlation

514 coefficient; crosses indicate non-significant correlations (p>0.05).

515 (D) Correlations between Flow-Seq measurements and GC3 content of 1<sup>st</sup> (nt 1-

516 360) and  $2^{nd}$  (nt 361 - 720) halves of GFP sequences.

(E) Protein and mRNA measurements of translational fusion constructs between
GC-poor (30% GC3, Kpoor) and GC-rich (85% GC3, Krich) variants of mKate2
with a GC-rich (97% GC3, Grich) or GC-poor (33%, Gpoor) variants of GFP. Data
represents the mean of 3 replicates, +/- SEM. GFP protein RFU, mKate protein
RFU and RNA AU were defined as in Figure 2.

(F) Protein fluorescence measurements of 2 GC-poor GFP variants (GFP\_154;
GC3=0.38 and GFP\_403; GC3=0.37) expressed either as unspliced constructs, or
with an intron placed within the 5' UTR, the CDS or both. Data represents the
mean of 3 replicates, +/- SEM. All intron-containing constructs differ significantly
from their intronless counterparts (p<0.05, t-test). GFP protein RFU were</li>
defined as (GFP fluorescence - background GFP fluorescence). See also Figures
S4 and S5.

529

#### 530 **Figure 4. High GC content increases cytoplasmic localisation of mRNA.**

531 (A) Stable HeLa pools expressing 217 GFP variants +/- intron were fractionated

532 into nuclear and cytoplasmic portions before RNA extraction. Specific markers of

- subcellular compartments were quantified by qRT-PCR before amplicon-librarypreparation.
- 535 (B) Relative cytoplasmic concentration (RCC) of unspliced and spliced GFP 536 variants. Data represents the mean of 2 replicates.  $***p=2\times10^{-6}$ .
- 537 (C) Correlation between GC3 content and RCC for unspliced and spliced GFP
- 538 RNA. Data points represent the means of 2 replicates.
- 539 (D) Correlation between RCC scores of unspliced and spliced GFP ( $R^2=0.1$ , 540 p=2.6×10<sup>-5</sup>). See also Figure S5.
- 541

#### 542 **Figure 5. High GC content leads to increased ribosome association.**

- (A) (Left) A stable pool of HEK293 cells expressing 217 unspliced GFP variants
  was subjected to polysome profiling using sucrose gradient centrifugation.
  (Right, from top to bottom) UV absorbance profile, GFP mRNA abundance,
  GAPDH mRNA abundance, ethidium bromide staining of gradient fractions. GFP
  and GAPDH mRNA were quantified by qRT-PCR.
- (B) RNA from collected fractions was combined into 4 pools (as indicated by
  coloured boxes) before amplicon library preparation for high-throughput
  sequencing: unbound ribonucleoprotein complexes (red), monosomes (yellow),
  light polysomes (light green) and heavy polysomes (dark green). Resulting read
  distributions (in %) for GFP variants are represented as heatmap.
- (C) Correlation plot between mean ribosome density (left panel) and ribosome
  association (right panel) of GFP variants and their corresponding GC3 content.
  Triangles indicate outliers (Ribosome association values 24.89 (GC3=0.84) and
  24.80 (GC3=0.90)). The ribosome density and ribosome association measures
  were calculated as described in the methods section.
- 558

#### 559 **Figure 6. Splicing-dependent codon usage shapes global gene expression.**

560 Effects of GC4 content on the expression of unspliced (y-axis) and spliced (x-axis) 561 endogenous human genes, both on RNA and protein level. Each point 562 corresponds to the regression coefficient of an individual experiment (cell line 563 and/or biological replicate). Error bars indicate the standard error of these 564 regression coefficients. Surrounding ellipses indicate the 95% confidence

- 565 interval for 1,000 bootstraps of underlying data (see Methods, Figure S6 and
- Table S1). The diagonal indicates x=y. See also Figure S6 and Table S1.

567

#### 569 **STAR Methods**

570

#### 571 Lead contact and materials availability

572

Further information and requests for resources and reagents should be directed
to, and will be fulfilled by, Grzegorz Kudla (gkudla@gmail.com). Plasmids
generated in this study will be distributed by Grzegorz Kudla.

576

#### 577 **Experimental model and subject details**

578

579 HeLa Flp-in T-Rex cells were obtained from the Andrew Jackson group, HEK293

580 Flp-in T-Rex cells were sourced from ThermoFisher, and HeLa cells were from

581

582

#### 583 **Genes and plasmids**

ATCC.

584 The library of 217 synonymous GFP variants used here consists of 138 variants 585 from an earlier study (Kudla et al., 2009), 59 new variants assembled using the PCR-based method described in (Kudla et al., 2009), and 22 variants that were 586 587 designed in silico and ordered as synthetic gene fragments (gBlocks) from 588 Integrated DNA Technologies (IDT) (Mittal et al., 2018). Each of the 22 variants 589 was designed by setting a target GC3 content (between 25 and 95%) and 590 randomly replacing each codon with one of its synonymous codons, such that the 591 expected GC3 content at each codon position corresponded to the target GC3 592 content. For example, to design a GFP variant with GC3 content of 25%, each 593 glycine codon was replaced with one of the four synonymous glycine codons 594 with the following probabilities: GGA, 37.5%; GGC, 12.5%, GGG, 12.5%; GGT, 595 37.5%. We also generated 23 mKate2 sequences using an analogous procedure 596 and ordered the variants as gBlocks from IDT. All the genes were cloned into the 597 Gateway Entry vector pGK3 (Kudla et al., 2009).

598

#### 599 **Construction of transient expression vectors**

600 Plasmids used in transient transfection experiments are based on pCI-neo 601 (Promega), a CMV-driven mammalian expression vector that contains a chimeric 602 intron upstream of the multiple cloning site (MCS) within the 5' UTR. This intron 603 consists of the 5' splice donor site from the first intron of the human beta-globin gene and the branch and 3' splice acceptor site from the intron of 604 605 immunoglobulin gene heavy chain variable region (see pCI-neo vector technical bulletin, Promega). This vector was adapted to be compatible with Gateway 606 607 recombination cloning by inserting the Gateway-destination cassette, RfA, using 608 the unique EcoRV and Smal restriction sites present within the MCS of pCI-neo, 609 generating pCM2. This plasmid was then further modified by removing the 610 intron contained within the 5' UTR by site-directed deletion mutagenesis using 611 Phusion-Taq (ThermoScientific) and primers 'pCI\_del\_F' and 'pCI\_del\_R' (see 612 Table S2 for list of all primers used), generating plasmid pCM1.

613 To be able to normalise spectrophotometric measurements from single GFP 614 transfection experiments, pCM1 and pCM2 were further modified to contain a separate expression cassette driving the expression of a second fluorescent 615 616 reporter gene, mKate2. The mKate2 gene cassette from pmKate2-N (Evrogen) 617 was inserted via Gibson assembly cloning: First, the entire mKate2 expression 618 cassette was amplified using primers 'mKate2\_gibs\_F' and 'mKate2\_gibs\_R' which 619 add overhangs homologous to the pCM insertion site. Next, pCM1 and pCM2 were linearised by PCR using primers 'pCI\_gib\_F' and 'pCI\_gib\_R'. All PCR 620 products were purified using the Qiagen PCR purification kit and fragments with 621 622 homologous sites recombined using the Gibson assembly cloning kit (NEB) 623 according to manufacturer's instructions (NEB). Successful integration was validated by Sanger sequencing. This generated plasmids pCM3 (-intron, 624 625 +mKate2) and pCM4 (+intron, +mKate2).

626

#### 627 Transient plasmid transfections for spectrofluorometric measurements

Plasmids for transient expression of fluorescent genes were transfected into
HeLa cells grown in 96-well plates. Per plasmid construct, 3 replicates were
tested by reverse transfection. Enough transfection mix for 4 wells was prepared
by diluting 280ng plasmid DNA in 40ul OptiMem (Gibco). 1ul Lipofectamine2000
(Invitrogen; 0.25ul per well) was diluted in 40ul OptiMem and incubated for

5min at room temperature. Both plasmid and Lipofectamine2000 dilutions were then mixed (80ul total volume) and further incubated for 20-30min. 20ul of transfection complex was then pipetted into each of 3 wells before adding 200ul of HeLa cell suspension (45,000 cells/ml; 9,000 cells/well) in phenol red-free DMEM (Biochrom, F0475). Media was exchanged 3-4h post-transfection to reduce toxicity. Cells were then grown for a further 24h or 48h at 37C, 5% CO2.

After incubation, cells were lysed by removing media and adding 200ul of cell
lysis buffer (25mM Tris, pH 7.4, 150mM NaCl, 1% Triton X-100, 1mM EDTA, pH
8). Fluorescence readings were obtained using a Tecan Infinite M200pro
multimode plate reader. The plate was first incubated under gentle shaking for
15min followed by fluorescence measurements using the following settings:
Ex486nm/Em 515nm for GFP and Ex588nm/Em633nm for mKate2; reading
mode: bottom; number of reads: 10 per well; gain: optimal.

For data analysis, measurements of untransfected cells were subtracted as background from all other wells. For comparability of different plates within a set of experiments, the same 3 genes were transfected on every plate to account for technical variability. In the screen of individual GFP variants (see Figure 2), GFP measurements were divided by mKate2 measurements from same wells to reduce noise caused by well-to-well variation in transfection efficiency, but similar results were obtained without normalisation.

653

#### 654 Transient transfections and RNA extraction for qRT-PCR analysis

655 HeLa cells were reverse transfected in 12-well plates using 800ng plasmid DNA 656 and 2ul Lipofectamine 2000 (Invitrogen). DNA and Lipofectamine 2000 were 657 diluted in 100ul OptiMEM (Gibco) each, incubated for 5min, mixed and further 658 incubated for 20min. The transfection complex was then added to each well 659 before adding  $10^5$  HeLa cells. Cells were incubated for 24h at 37C, 5% CO2 660 before harvesting. Cells were then harvested by adding 1ml Trizol reagent (Life 661 technologies). RNA was extracted according to manufacturer's instructions. 662 Resulting RNA was further treated with DNAse I using the Turbo DNase kit 663 (Ambion) to remove any residual plasmid and genomic DNA.

664

#### 665 **RT-PCR analysis**

666 cDNA for qRT-PCR analysis was prepared using SuperScript III Reverse 667 Transcriptase (Life technologies) according to the manufacturer's recommendations with 500ng total RNA as template and 500ng random 668 669 hexamers (Promega). All qRT-PCRs were carried out on a Roche LightCycler 480 670 using Roche LightCycler480 SYBR Green I Master Mix and 0.3uM gene-specific 671 primers. Samples were analysed in triplicate as 20ul reactions, using 2ul of 672 diluted cDNA. Cycling settings: DNA was first denatured for 5min at 95°C before 673 entering a cycle (50-60x) of denaturing for 10sec at 95°C, annealing for 7sec at 674 55-60°C (depending on primers used), extension for 10sec at 72°C and data 675 acquisition. DNA was then gradually heated up by 2.20 °C/s from 65 to 95°C for 676 5sec each and data continuously collected (Melting curve analysis). Data was 677 evaluated using the comparative Ct method (Livak and Schmittgen, 2001). RNA 678 measurements from transient transfection experiments were normalised to the 679 abundance of neomycin resistance marker (NeoR) RNA, which is expressed from 680 the same plasmid, to control for differences in transfection efficiency (primers 'Neo\_F' and 'Neo\_R'). PCRs performed on cDNA from stable Flp-in T-Rex cell lines 681 682 to measure splicing efficiency were performed on an Eppendcorf Mastercycler nexus X2 in 20ul reaction volumes, using Accuprime Pfx (ThermoFisher) 683 684 according to manufacturer's instructions, using 0.3uM primers (intron-685 independent: pc5\_5UTR\_F & pc5\_3UTR\_R1; intron specific: pc5\_INT\_F & 686 pc5\_3UTR\_R2).

687

#### 688 Subcellular fractionation

689 This protocol is based on the cellular fractionation protocol published by 690 (Gagnon et al., 2014) but includes a further clean-up step using a sucrose cushion 691 as described by (Zaghlool et al., 2013) and a second lysis step as described by 692 (Wang et al., 2006). Cell lysis and nuclear integrity was monitored throughout by 693 light microscopy following Trypan blue staining (Sigma). Cells were grown in 694 10cm plates for 24h to about 90% confluency. Cells were then washed with PBS 695 and trypsinised briefly using 1ml of 1xTrypsin/EDTA. After stopping the reaction 696 with 5ml DMEM, cells were transferred into 15ml falcon tubes and collected by 697 spinning at 100g for 5min. Resulting cell pellets were resuspended in 500ul ice-698 cold PBS, transferred into 1.5ml reaction tubes and spun at 500g for 5min, 4°C.

The supernatant was discarded and cells resuspended in 250ul HLB (10mM Tris (pH 7.5), 10mM NaCl, 3mM MgCl2, 0.5% (v/v) NP40, 10% (v/v) Glycerol, 0.32M sucrose) containing 10% RNase inhibitors (RNasin Plus, Life Technologies) by gently vortexing. Samples were then incubated on ice for 10min. After incubation, samples were vortexed gently, spun at 1000g for 3min, 4°C, and supernatants and pellets were processed separately as indicated in a) and b) below.

a) Cytoplasmic extract:

The supernatant was carefully layered over 250ul of a 1.6M sucrose cushion and
spun at 21,000g for 5min. The supernatant was then transferred into a fresh
1.5ml tube and 1ml Trizol was added and mixed by vortexing.

b) Nuclear extract:

711 The pellets were washed 3 times with HLB containing RNase inhibitors by gently 712 pipetting up and down 10 times followed by a spin at 300g for 2min. After the 713 3rd wash, nuclei were resuspended in 250ul HLB and 25ul (10%) of detergent 714 mix (3.3% (wt/wt) sodium deoxycholate/6.6% (vol/vol) Tween 40) dropwise 715 added while vortexing slowly (600rpm). Nuclei were then incubated for 5min on 716 ice before spinning at 500g for 2min. The supernatant was discarded and pellets 717 resuspended in 1ml Trizol (Ambion) by vortexing. 10ul 0.5M EDTA are added to 718 each nuclear sample in Trizol and tubes heated to 65°C for 10min to disrupt very 719 strong Protein-RNA and DNA-RNA interactions. Tubes were then left to reach 720 room temperature and RNA was extracted following the manufacturer's 721 instructions.

722

#### 723 Transcription inhibition assay

724 HeLa T-Rex Flp-in cell lines were grown to 80-90% confluency in 6 well for 24h 725 before treatment with 500nM Triptolide (Sigma). Cells were harvested at 726 indicated time points and RNA extracted using the Qiagen RNeasy kit (Qiagen, 727 74104). Control cells were treated with an equal volume of DMSO (drug carrier). 728 To assess transcript levels, qRT-PCR was performed as described above using 729 primers 'pc5\_3UTR\_F' and 'pc5\_3UTR\_R1'. GFP levels were normalised to levels 730 of 7SK, a RNA polymerase III-transcribed non-coding RNA, whose expression 731 levels are not affected by Triptolide treatment. Relative transcript levels of c-Myc

- are shown as an example of a relatively unstable transcript, while levels of Gapdh
- are shown as a stable transcript. Transcript half-lives  $(t_{1/2})$  were calculated by
- first fitting an exponential decay curve,  $y(x) = a \times e^{kx}$ , through the data points
- to obtain the decay constant *k*. The half-life is then calculated as  $t_{1/2} = \ln(2)/k$ .
- 736

#### 737 Generation of stable Flp-in cell lines

We adopted a multiplex-Gateway integration method to create a pool of 217 GFP plasmids which are compatible with the T-Rex Flp-in system (Invitrogen) for creating stable, doxycycline-inducible cell lines, in which each variant is expressed from the same genomic locus, allowing direct comparison of expression levels.

743 pcDNA5/FRT/TO/DEST (Aleksandra Helwak, University of Edinburgh) contains 744 the Gateway-compatible attB destination cassette to allow the subcloning of 745 genes from any Gateway-entry vectors. This plasmid was further modified to 746 contain the same 5' UTR intron sequence as in pCM4 used in transient 747 expression experiments using Gibson Assembly (NEB): the intronic sequence 748 was amplified from pCM4 by PCR using primers 'Gib\_intr\_F' and 'Gib\_intr\_R' 749 using Q5 High-Fidelity Polymerase (NEB). The primers added 15nt overhangs 750 which are homologous to the ends of pcDNA5/FRT/TO/DEST when linearised with AfIII. The Gibson assembly reaction was performed as per manufacturer's 751 752 instructions (NEB), generating pcDNA5/FRT/TO/DEST/INT.

753 217 individual GFP variants stored in Gateway-entry vector pGK3 were mixed 754 with a concentration of 0.06ng of each GFP variant. For each pcDNA5 destination 755 vector, a separate Gateway LR reaction was set-up in a total volume of 45ul using 756 500ng destination vector, 5ul LR Clonase enzyme mix, 38ul of the mixed 217 757 pGK3-GFP plasmids and TE (pH 8). The reactions were incubated at 25C 758 overnight followed by Proteinase K digest (5ul, LR Clonase kit) for 10min at 37C. 759 The total 50ul reaction mix was transformed into 2.5ml highly competent 760 DH5alpha in a 15ml Falcon tube by heat-shocking cells for 2min 30s at 42C, 761 followed by cooling on ice for 3min, before adding 10ml SOC medium and 762 incubating while shaking for 1h at 37C. After incubation, cells were spun down at 763 3000g for 3min and resulting bacterial pellets resuspended in 1ml fresh SOC. 764 10x100ul were plated onto L-Ampicillin agar plates and incubated overnight at 37C resulting in >800 colonies per plate. Bacterial colonies were scraped off the
plates and collected in a falcon tube. Plasmid DNA was extracted using a Qiagen
Midiprep kit according to the manufacturer's instructions, resulting in two
plasmid pools: pCDNA5/GFPpool and pcDNA5/INT/GFPpool. Both pools were
subjected to high-throughput sequencing to confirm the presence of different
GFP variants.

771 HeLa T-Rex Flp-in cells (gifted by the Andrew Jackson lab, The University of Edinburgh) and HEK293 T-Rex Flp-in (Thermo Scientific) were grown to 80% 772 773 confluency in 6 well plates. For GFP plasmid pool transfections, 774 pCDNA5/GFPpool or pCDNA5/INT/GFPpool were mixed in a 9:1 ratio with the 775 Flp-recombinase expression plasmid pOG44 (Invitrogen) to give 2ug in total 776 (1.8ug pOG44 + 0.2ug pCDNA5) and diluted in OptiMEM (Gibco) to 100ul. 777 Transfections were performed with 9ul Lipofectamine2000 (Invitrogen) and 778 91ul OptiMEM per well by incubating 5min at room temperature before mixing 779 with plasmid DNA and a further 15min incubation. The transfection mix was 780 then added dropwise to the cells. Media were replaced with conditioned media 781 4h post-transfection. Cells were incubated for further 48h before chemical 782 selection to select for successful gene integration using 10ng/ul Blasticidin S 783 (ThermoFisher) and 400mg/ml (HeLa T-Rex Flp-in) or 100mg/ml (HEK293 T-784 Rex Flp-in) Hygromycin B (Life Technologies). Successful selection was 785 determined by monitoring cell death in untransfected cells. Chemically resistant 786 cells represent pools of cell lines expressing different GFP variants from the 787 same genomic locus. High-throughput sequencing of the GFP integration site 788 within each generated cell line pool confirmed the successful integration of all 789 variants.

HeLa T-Rex Flp-in and HEK293 T-Rex Flp-in cell lines expressing individual
intron-containing and intronless GFP variants were generated using the same
protocol.

793

#### 794 Flow-Seq: FACS sorting and genomic DNA extraction

80x15cm cell culture plates of HeLa T-Rex Flp-in GFP pool cells and 40x15cm cell
culture plates of HEK293 T-Rex Flp-in GFP pool cells were induced with 1ug/ml
Doxycyline (Sigma, D9891) in phenol red-free DMEM (Biochrom, F0475)

798 supplemented with 10% FCS (Sigma, F-7524) and 2mM L-Glutamine. After 24h 799 or 48h, cells were harvested by gentle trypsinisation and cells were sorted into 8 800 fluorescence bins using a BD FACS Aria II cell sorter. To define the range of GFP 801 positive signal, cells without stable GFP expression were used as negative 802 control. 80% of HeLa and 90% HEK293 GFP pool cells fell into the GFP-positive range. Each fluorescence bin was chosen to comprise roughly 10% of the GFP-803 804 positive population. The bin spacing was kept the same for the sorting of HeLa 805 cell pools expressing unspliced and spliced GFP variants to allow direct 806 comparisons of the fluorescence profiles of individual variants.

807 About 10<sup>7</sup> cells per bin were collected in Polypropylene collection tubes (Falcon) 808 coated with 1% BSA/PBS, cushioned with 200ul 20%FBS/PBS. Cell suspensions 809 were decanted into 15ml tubes and cells collected by spinning 5min at 500g. The 810 supernatant was transferred into fresh 15ml tubes and precipitated using 2 811 volumes of 100% EtOH/0.1 volume Sodium Acetate (pH 5.3) and 10ul Glycoblue 812 (Ambion). Tubes were shaken vigorously for 10s before incubating at -20C for 15min, followed by spinning at 3000g for 20min. Resulting pellets were air-813 814 dried, resuspended in 1ml digest buffer (100mM Tris pH 8.5, 5mM EDTA, 0.2% 815 SDS, 200mM NaCl) and then combined with the respective cell pellet. 10ul RNAse 816 A (Qiagen, 70U) was added and samples gently rotated at 37C. After 1h, 1ul/ml 817 Proteinase K (20mg/ml, Roche) was added to the samples before rotating a further 2h at 55C. Genomic DNA was purified 3 times by using 1 volume 818 819 Phenol:Chloroform:Isoamyl alcohol (PCI, 25:24:1, Sigma). After each addition of 820 PCI, samples were shaken vigorously for 10s before spinning at 3000g for 20min 821 (first extraction) or 5min (all following). The resulting bottom layers including 822 the interphase were removed before each PCI addition. After the last PCI 823 extraction, the upper layer was transferred into a fresh 15ml tube and 1 824 extraction performed using 1 volume chloroform: isoamyl alcohol (CI.24:1, 825 Sigma). After a 5min spin at 3000g, the upper layer was transferred into a fresh 826 15ml tube and DNA precipitated using EtOH/Sodium Acetate as before. After a 827 5min incubation on ice, DNA was collected by spinning for 30min at 3000g. The 828 resulting DNA pellets were washed 2 times with 75% EtOH before air-drying and 829 resuspending in 200ul Tris-EDTA (10mM). The quality of the extracted genomic 830 DNA was assessed on a 0.8% Agarose/TBE gel.

831

#### 832 Polysome profiling

833 HEK293 Flp-in GFP pool cell lines were grown to 90% confluency on 15cm 834 dishes. Cells were treated for 20min with 100ug/ul Cycloheximide before 835 harvesting cells by removing media, washing with 2x ice-cold PBS followed by 836 scraping cells into 1ml PBS and transferring into 1.5ml tubes. Cells were pelleted at 7000rpm, 4°C for 1min and resulting cell pellet carefully resuspended by 837 838 pipetting up and down in 250ul RSB (10x RSB: 200mM Tris (pH 7.5), 1M KCl, 839 100mM MgCl2) containing 1/40 RNasin (40U/ul, Promega), until no clumps 840 were visible. 250ul of polysome extraction buffer was then added (1ml 10x RSB 841 + 50ul NP-40 (Sigma) + 9ml H2O + 1 complete mini EDTA-free protease inhibitor 842 pill (Roche)) and lysate passed 5x through a 25G needle avoiding bubble 843 formation. The lysate was then incubated on ice for 10min before spinning 844 10min at 10,000g, 4°C. The supernatant was then transferred into a fresh 1.5ml 845 tube and the RNA concentration estimated by measuring the OD at 260nm. Sucrose gradients (10-45%) containing 20 mM Tris, pH 7.5, 10 mM MgCl2, and 846 847 100 mM KCl were made using the BioComp gradient master. 100ug of Lysate 848 were loaded on sucrose gradients and spun at 41,000rpm for 2.5h in a Sorvall 849 centrifuge with a SW41Ti rotor. Following centrifugation, gradients were 850 fractionated using a BioComp gradient station model 153 (BioComp 23 851 Instruments, New Brunswick, Canada) by measuring cytosolic RNA at 254 nm 852 and collecting 18 fractions.

853 RNA from all fractions was precipitated using 1 volume of 100% EtOH and 1ul 854 Glycoblue (Ambion), before extracting RNA using the Trizol method (Life 855 Technologies). Equal volumes of RNA of each fraction was run on a 1.3% 856 Agarose/TBE gel to assess the quality of fractionation and RNA integrity. 857 Additionally, equal volumes of RNA of each fraction were used in cDNA synthesis 858 using SuperScript III (ThermoFisher) and 2uM gene-specific primers for GFP 859 ('pcDNA5-UTR\_R') and GAPDH ('GAPDH\_R') followed by qRT-PCR analysis. For 860 high-throughput sequencing, total RNA from collected fractions was combined in 861 equal volumes into 4 pools (as indicated in Figure 5B; free ribonucleoprotein 862 (RNP) complexes, monosomes, light polysomes (2-4) and heavy polysomes (5+)) 863 before amplicon library preparation (as described below).

864

#### 865 High-throughput library preparation and sequencing

866 Sequencing libraries were generated by PCR using primers specific for GFP 867 amplification (Table S2) which carry the required adaptor sequences for paired-868 end MiSeq sequencing, as well as 6nt indices for library multiplexing. Between 6-869 10ug of total genomic DNA were used in multiple PCR reactions (200ng per 50ul 870 reaction). All PCRs were performed using Accuprime Pfx (NEB) according to 871 manufacturer's recommendations using 0.4ul Accuprime Pfx Polymerase and 872 0.3uM of each primer ('PE\_PCR\_left' and 'S\_indexX\_right\_PEPCR'). The cycling 873 conditions were as follows: Initial denaturation at 95C for 2min, followed by 30 874 cycles of denaturation at 95C for 15sec, annealing at 51C for 30sec, extension at 875 68C for 1min. The final extension was performed at 68C for 2min. After PCR, all 876 reactions of the same template were pooled and 1/3 of the reaction purified 877 using the Qiagen PCR purification kit according to the manufacturer's 878 instructions. DNA was eluted in 50ul H2O. Library size selection was performed 879 using the Invitrogen E-gel system (Clonewell gels, 0.8% agarose) followed by 880 Qiagen MinElute PCR purification. Correct fragment sizes were confirmed and 881 quantified using the Agilent Bioanalyzer 2100 system.

882 For library preparation of RNA samples, 500ng RNA was first converted into 883 cDNA using 2nmol GFP-specific primers ('S\_indexX\_right\_PEPCR') using 884 SuperScript III (Life technologies) according to manufacturer's protocol, using 885 50C as extension temperature. Resulting cDNA was then treated with 1ul 886 RNaseH (NEB) for 20min at 37C, followed by heat inactivation at 65C for 5min. 887 Samples were diluted 1:2.5 before using 2ul as template in PCR for library 888 preparation. A minimum of 8x50ul PCR reactions were set up and pooled for 889 each sample before PCR purification, followed by E-gel purification as described 890 above.

High-throughput sequencing was conducted by Edinburgh Genomics (The
University of Edinburgh) and Imperial BRC Genomics facility (Imperial College
London) using the Illumina MiSeq platform (2x300nt paired-end reads).

894

#### 895 4sU labelling and separation of nascent RNA

896 GFP expression was induced for 24h using 1ug/ml Doxycyline (Sigma, D9891) at 897 80% confluency in 15cm cell culture dishes. To label nascent RNA, 4sU (Sigma, 898 T4509) was added to the media to a final concentration of 500 uM. Cells were 899 then further incubated at 37C, 5%CO2 for 20min. After incubation, cells were 900 harvested using 5ml Trizol reagent and RNA extracted following manufacturer's 901 instructions using 1ml Chloroform and Phase Lock Gel Heavy tubes (15ml, 902 Eppendorf). Resulting RNA pellet was resuspended in 100ul RNAse-free water, 903 followed by a DNAse digest step using the TURBO DNA-free kit (Ambion) 904 following manufacturer's instructions.

905 Biotin labelling reactions were set up as following: 100ug RNA + 2ul Biotin-HPDP 906 (1mg/ml in DMF; Pierce, 21341) + 1ul 10x Biotinylation buffer (100mM Tris pH 907 7.4, 10mM EDTA) + H2O to 1ml. Reactions were then incubated for 1.5h at RT 908 with rotation. Unincorporated biotin-HPDP was removed by 2 x chloroform 909 extraction (1 volume) using Phase lock tubes (2ml, Eppendorf). The upper phase 910 was then transferred to a DNA lobind tube (Eppendorf, 0030108051) and RNA precipitated using 1/10 reaction volume 5M NaCl and an equal reaction volume 911 912 of 100% Isopropanol. Resulting RNA pellet was washed with 70% Ethanol before 913 resuspending biotinylated RNA in 100ul RNAse-free water.

914 Streptavidin pull-down reactions were set up using 100ul biototinylated RNA 915 (up to 100ug RNA) + 100ul Streptavidin beads (Miltenyi, 130074101) and 916 reaction incubated for 15min at RT with gentle shaking. Streptavidin beads were 917 then isolated using uMACS columns (Miltenyi, 130074101) attached to a 918 magnetic stand. Columns were equilibrated with Washing buffer (WB; 100mM 919 Tris pH 7.5, 10mM EDTA, 1M NaCl, 0.1% Tween20) before adding Streptavidin 920 reaction mixtures to the column. Columns were then washed 3 times with WB 921 heated to 65C, followed by 3 times with WB at RT. RNA was then eluted using 922 100ul freshly prepared 100mM DTT, followed by purification using the Qiagen 923 RNeasy Minelute kit (Qiagen, 74204). RNA was eluted in 20ul RNAse-free water 924 and concentration determined using the Qubit RNA HS assay kit (Life 925 technologies, Q32852). cDNA synthesis was performed using equal amounts of 926 RNA across all samples using SuperScript III and qRT-PCRs performed as 927 described in section 'RT-PCR analysis' using primers specific for the 3' UTR 928 ('pc5\_3UTR\_F' + 'pc5\_3UTR\_R1') and intronic sequence ('pCI-premRNA\_F' + 'pCI929 premRNA-R').

#### 930 Quantification and Statistical analysis

931

#### 932 Analysis of GFP pool experiments

Raw sequencing files (database accession number PRJNA596086) were
demultiplexed by 6nt indices by the respective sequencing facility. To remove
the plasmid sequence, the second reads from paired-end sequencing were
trimmed using flexbar (-as ATGTGCAGGGCCGCGAATTCTTA -ao 4 -m 15 -u 30).
Reads were then mapped to the GFP library using bowtie2 (-X 750) and filtered
using samtools (-f 99).

For Flow-seq data, only variants with a minimum of 1000 reads across all 8
sequencing bins were used for further analysis. For each GFP variant, the
number of reads in each bin (n(i)) was multiplied by the respective bin index (i)

942 before taking the sum and dividing by the total number of reads across all bins:

943 Fluorescence (variant) =  $\sum_{i=1}^{8} i * n(i) / \sum_{i=1}^{8} n(i)$ 

944 For cell fractionation experiments, only data with a minimum of 1000 reads 945 across both cytoplasmic and nuclear fractions was used to calculate the relative n(cyto)

946 cytoplasmic concentration ('RCC') for each variant:  $RCC = \frac{n(cyto)}{n(cyto) + n(nuc)}$ 

For polysome profiling, only variants with a minimum of 1000 reads across all 4 sequencing bins were used for further analysis. To estimate ribosome density, for each GFP variant, the number of reads in each bin (n(i)) was multiplied by the respective bin index i (free RNA, i=1; monosomes, i=2; light polysomes, i=3; heavy polysomes, i=4) before taking the sum and dividing by the total sum of reads across all fractions:

953 *Ribosome density(variant)* =  $\sum_{i=1}^{4} i * n(i) / \sum_{i=1}^{4} n(i)$ 

954 Ribosome association for each variant was calculated as the sum of reads (n) in

955 light polysomes, heavy polysomes and monosomal fractions, divided by the sum

- 956 of reads found in the free RNP fraction:
- 957 Ribosome association(variant) =
- 958  $\frac{(n(monosomes) + n(light polysomes) + n(heavy polysomes))}{n(free RNPs)}$

959

### 960 **Definition of calculated sequence features**

- 961 GC3: GC content in the third position of codons
- 962 CpG: number of CpG dinucleotides
- 963 dG: The minimum free energy of predicted mRNA secondary structure around
- 964 the start codon was calculated using the hybrid-ss-min program version 3.8
- 965 (default settings: NA = RNA, t = 37, [Na+] = 1, [Mg++] = 0, maxloop = 30, prefilter
- 966 = 2/2) in the 42-nt window (-4 to 38) as in (Kudla et al., 2009).
- 967 CAI: Codon Adaptation Index (*H. sapiens*) (Sharp and Li, 1987a) was calculated
- 968 using a reference list of highly expressed human genes collected from the EMBL-
- 969 EBI expression atlas https://www.ebi.ac.uk/gxa.
- 970 tAI: tRNA adaptation index (dos Reis et al., 2004)
- 971 ARE: top score of ATTTA motif match in each sequence.
- 972 AT-stretch: number of times motif (AT){9} was identified in each sequence.
- 973 GC-stretch: number of times motif (GC){9} was identified in each sequence.
- 974 Poly\_A: number of times the position-specific scoring matrix
  975 ((47,3,0,50)(18,6,9,67)(53,12,12,23)(59,6,0,35)(70,6,6,18)) was identified in
  976 each sequence.
- 977 SD\_cryptic: number of times RSGTNNHT motif was identified in each sequence.
- 978 SD\_PSSM: number of times the position-specific scoring matrix
- 979 ((60,13,13,14)(9,3,80,7)(0,0,100,0)(0,0,0,100)(53,3,42,3)(71,8,12,9)(7,6,81,6)(1

980 6,17,21,46)) was identified in each sequence.

981

FIMO (http://meme-suite.org) was calculated to identify and count sequence
motifs. Open-source packages available for R were used for generating
correlation matrices (corrplot), heatmaps (ggplot2), boxplots
(graphics/ggplot2), The GC3 of all human coding sequences (assembly:
GRCg38\_hg38; only CDS exons) was calculated using R package 'seqinr'.

987

#### 988 Analysis of GC content variation in the human genome

The GRCh38 sequence of the human genome, as well as the corresponding gene
annotations (Ensembl release 85), was retrieved from the Ensembl FTP site
(Zerbino et al., 2018). The full coding sequences (CDSs) of protein-coding genes

992 were extracted, filtered for quality and clustered into putative paralogous 993 families (see (Savisaar and Hurst, 2016) for full details). For all analyses, a 994 random member was picked from each putative paralogous cluster. In addition, 995 only one transcript isoform (the longest) was considered from each gene. Note 996 that exon rank was always counted from the first exon of the gene, even if it was 997 not coding. In Figure 1A, density was calculated using the ggplot2 998 geom\_density() function. For Figure 1C, GC4 was averaged across all sites that 999 were at the same nucleotide distance to the TSS and within an exon of the same 1000 rank. For the functional retrocopies analysis, the parent-retrocopy genes derived 1001 in (Parmley et al., 2007) were used. Pseudogenic retrocopies were retrieved 1002 from RetrogeneDB (Rosikiewicz et al., 2017). Retrocopy annotations were 1003 filtered to only leave human genes with a one-to-one ortholog in Macaca 1004 *mulatta*. Next, only ortholog pairs where both the human and the macaque copy 1005 were annotated as not having an intact reading frame and where the human 1006 copy was annotated as KNOWN\_PSEUDOGENE were retained. For the analyses 1007 reported in Figure S1, the functional retrocopies were also retrieved from 1008 RetrogeneDB, as we could not access genomic locations for the (Parmley et al., 1009 2007) set. The functional retrogenes were retrieved similarly to pseudogenes, 1010 except that both the human and the macaque copy were required to have an 1011 intact open reading frame and the human copy could not be annotated as 1012 KNOWN\_PSEUDOGENE.

- 1013 Python 3.4.2. was used for data processing and R 3.1.2 was used for statistics and1014 plotting (R Development Core Team, 2005).
- 1015

#### 1016 **Computation methods for analysis of endogenous gene expression**

#### 1017 **Data Collection**

- 1018 See also Table S1 for summary of datasets used.
- 1019
- GC4 content was calculated for each protein-coding transcript annotated in GENCODE version 19 as the GC content of the third codon position across all fourfold-degenerate codons (CT\*, GT\*, TC\*, CC\*, AC\*, GC\*, GA\*, CC\*, GC\*). The core promoter of each transcript is further defined as -300 bp/+100 bp around the annotated TSS.

The level of transcription initiation was quantified in K562 and Gm12878
 cells as the number of GRO-cap reads from the same strand which overlap
 the core promoter.

- 1028 3. Nuclear stability was assessed using CAGE data obtained in triplicate from 1029 Egfp, Mtr4 and Rrp40 knockdowns (GSE62047; (Andersson et al., 2014)). 1030 Similarly to the approach used for the GRO-cap data, we calculated the 1031 RPKM across core promoters for each library separately. The baseMean expression for each treatment was quantified using DESeq2, where 1032 1033 promoters with no reads across any replicate were first removed from 1034 each comparison. Nuclear stability was then assessed as the fold-change 1035 between the Egfp and Mtr4 knockdown and cytoplasmic stability by the 1036 estimated fold-change between the Mtr4 and Rrp40 knockdowns.
- 1037 4. The level of the mature mRNA was quantified using RNA-seq libraries 1038 from whole cell samples (prepared as described elsewhere for HEK293 1039 cells downloaded and from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncod 1040 1041 eCshlLongRnaSeq for Gm12878, HepG2, HeLa, Huvec and K562 cells). 1042 Reads were pseudoaligned against GENCODE transcript models using 1043 Kallisto, set with 100 bootstraps. All other parameters were left at their 1044 default. Transcript expressions were extracted as the estimated TPM 1045 (tags per million) values.
- 10465. The level of the mature mRNA in the nuclear and cytoplasmic fractions1047was quantified using Kallisto as previously. As transcript stability was1048similar in both fractions (linear regression coefficient 0.97, p < 2.2×10<sup>-16</sup>),1049nuclear export was determined as the fraction TPM from these two1050compartments which was present in the nuclear fraction.
- 10516. Ribosome-sequencing data from HEK293 (GSE94460) and HeLa1052(GSE79664) cells were used to quantify the level of mRNA translation in1053these two cells. Both of these measures were determined at the gene1054level, and so these observations were applied to all GENCODE transcripts

- 1055annotated to these associated genes. These data were normalised to the1056mean mRNA expression in the relevant cell types (from step 4).
- 10577. Protein expression was assessed using mass-spectrometry data (Geiger et1058al., 2012) (Supp. Table 2) as the mean LFQ intensity across three1059replicates for each uniprot-annotated gene in each cell line for which data1060were available. Only data from genes where the UniProt ID is uniquely1061linked to a single transcript were considered in the analyses presented1062here.
- 1063 8. Protein stability was calculated as the level of the mature protein in
  1064 HEK293 and HeLa cells (step 7) relative to the mean rate of mRNA
  1065 translation in these cells (step 6).

### 1066 **Regression modelling**

1067 A pseudocount of 0.0001 was added to each measurement of gene expression 1068 and, excluding the nuclear export data, these values were then log2-transformed 1069 to generate a normal distribution of expression for subsequent analysis. 1070 Transcripts with an expression value of 0 were removed from downstream 1071 analysis and the resulting distributions used for regression analysis are 1072 displayed in Figure S6. Transcripts were separated into unspliced and spliced, 1073 where splicing was defined as containing more than one exon in the GENCODE 1074 transcript model. Expression measurements were then linearly regressed 1075 against the GC4 content separately for each class of transcript and the 1076 coefficients along with their associated standard errors. These data were then 1077 bootstrapped by sampling with replacement and recalculating the regression coefficients for spliced and unspliced transcripts. The 95% confidence interval of 1078 1079 these coefficients (discounting the standard error in these estimations) obtained 1080 by 1,000 samplings of this type was used to draw the ellipses shown in Figure 6.

1081 **Data and Software availability** 

1082 Raw sequencing files have been deposited in SRA and can be accessed under

1083 database accession number PRJNA596086.

- 1084
- 1085

| 1086                         | Reference list   |
|------------------------------|--|
| 1087                         |  |
| 1088                         |  |
| 1089<br>1090<br>1091<br>1092 | Andersson, R., Refsing Andersen, P., Valen, E., Core, L.J., Bornholdt, J., Boyd, M.,<br>Heick Jensen, T., and Sandelin, A. (2014). Nuclear stability and transcriptional<br>directionality separate functionally distinct RNA species. Nature<br>communications 5, 5336. |
| 1093                         | Arango, D., Sturgill, D., Alhusaini, N., Dillman, A.A., Sweet, T.J., Hanson, G.,   |
| 1094                         | Hosogane, M., Sinclair, W.R., Nanan, K.K., Mandler, M.D., et al. (2018). Acetylation   |
| 1095<br>1096                 | of Cytidine in mRNA Promotes Translation Efficiency. Cell <i>175</i> , 1872-1886 e1824.  |
| 1097                         | Arhondakis, S., Auletta, F., and Bernardi, G. (2011). Isochores and the regulation   |
| 1098                         | of gene expression in the human genome. Genome Biol Evol 3, 1080-1089.   |
| 1099                         | Bauer, A.P., Leikam, D., Krinner, S., Notka, F., Ludwig, C., Langst, G., and Wagner,   |
| 1100                         | R. (2010). The impact of intragenic CpG content on gene expression. Nucleic  |
| 1101                         | Acids Res <i>38</i> , 3891-3908.   |
| 1102                         | Bazzini, A.A., Del Viso, F., Moreno-Mateos, M.A., Johnstone, T.G., Vejnar, C.E., Qin,  |
| 1103                         | Y., Yao, J., Khokha, M.K., and Giraldez, A.J. (2016). Codon identity regulates mRNA  |
| 1104                         | stability and translation efficiency during the maternal-to-zygotic transition.  |
| 1105                         | EMBO J <i>35</i> , 2087-2103.  |
| 1106                         | Bentele, K., Saffert, P., Rauscher, R., Ignatova, Z., and Bluthgen, N. (2013). Efficient   |
| 1107                         | translation initiation dictates codon usage at gene start. Mol Syst Biol 9, 675.   |
| 1108                         | Bernardi, G. (1993). The vertebrate genome: isochores and evolution. Mol Biol  |
| 1109                         | Evol 10, 186-204.  |
| 1110                         | Burow, D.A., Martin, S., Quail, J.F., Alhusaini, N., Coller, J., and Cleary, M.D. (2018).  |
| 1111                         | Attenuated Codon Optimality Contributes to Neural-Specific mRNA Decay in   |
| 1112                         | Drosophila. Cell reports 24, 1704-1712.  |
| 1113<br>1114                 | Cambray, G., Guimaraes, J.C., and Arkin, A.P. (2018). Evaluation of 244,000 synthetic sequences reveals design principles to optimize translation in   |
| 1114                         | Escherichia coli. Nat Biotechnol <i>36</i> , 1005-1015.  |
| 1115                         | Carels, N., and Bernardi, G. (2000). Two classes of genes in plants. Genetics 154,   |
| 1110                         | 1819-1825.   |
| 1118                         | Courel, M., Clement, Y., Bossevain, C., Foretek, D., Vidal Cruchez, O., Yi, Z., Benard,  |
| 1119                         | M., Benassy, M.N., Kress, M., Vindry, C., et al. (2019). GC content shapes mRNA  |
| 1120                         | storage and decay in human cells. eLife 8.   |
| 1121                         | Dittmar, K.A., Goodenbour, J.M., and Pan, T. (2006). Tissue-specific differences in  |
| 1122                         | human transfer RNA expression. PLoS Genet 2, e221.   |
| 1123                         | Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar,   |
| 1124                         | L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., <i>et al.</i>   |
| 1125                         | (2012). Topology of the human and mouse m6A RNA methylomes revealed by   |
| 1126                         | m6A-seq. Nature 485, 201-206.  |
| 1127                         | dos Reis, M., Savva, R., and Wernisch, L. (2004). Solving the riddle of codon usage  |
| 1128                         | preferences: a test for translational selection. Nucleic Acids Res <i>32</i> , 5036-5044.  |
| 1129<br>1130                 | Duan, J., Shi, J., Ge, X., Dolken, L., Moy, W., He, D., Shi, S., Sanders, A.R., Ross, J., and Gejman, P.V. (2013). Genome-wide survey of interindividual differences of RNA  |
| 1130                         | stability in human lymphoblastoid cell lines. Scientific reports 3, 1318.  |
| 1131                         | Duret, L., and Galtier, N. (2009). Biased gene conversion and the evolution of   |
| 1132                         | mammalian genomic landscapes. Annu Rev Genomics Hum Genet <i>10</i> , 285-311.   |

| 1134 | Eyre-Walker, A.C. (1991). An analysis of codon usage in mammals: selection or            |
|------|--|
| 1135 | mutation bias? J Mol Evol 33, 442-449.   |
| 1136 | Fath, S., Bauer, A.P., Liss, M., Spriestersbach, A., Maertens, B., Hahn, P., Ludwig, C., |
| 1137 | Schafer, F., Graf, M., and Wagner, R. (2011). Multiparameter RNA and codon               |
| 1138 | optimization: a standardized tool to assess and enhance autologous mammalian             |
| 1139 | gene expression. PLoS One 6, e17596.   |
| 1140 | Gagnon, K.T., Li, L., Janowski, B.A., and Corey, D.R. (2014). Analysis of nuclear        |
| 1141 | RNA interference in human cells by subcellular fractionation and Argonaute               |
| 1142 | loading. Nat Protoc <i>9</i> , 2045-2060.  |
| 1143 | Galtier, N., Roux, C., Rousselle, M., Romiguier, J., Figuet, E., Glemin, S., Bierne, N., |
| 1144 | and Duret, L. (2018). Codon Usage Bias in Animals: Disentangling the Effects of          |
| 1145 | Natural Selection, Effective Population Size, and GC-Biased Gene Conversion. Mol         |
| 1146 | Biol Evol <i>35</i> , 1092-1103.   |
| 1147 | Geiger, T., Wehner, A., Schaab, C., Cox, J., and Mann, M. (2012). Comparative            |
| 1148 | proteomic analysis of eleven common cell lines reveals ubiquitous but varying            |
| 1149 | expression of most proteins. Mol Cell Proteomics 11, M111 014050.                        |
| 1150 | Gingold, H., Tehler, D., Christoffersen, N.R., Nielsen, M.M., Asmar, F., Kooistra,       |
| 1151 | S.M., Christophersen, N.S., Christensen, L.L., Borre, M., Sorensen, K.D., et al.         |
| 1152 | (2014). A dual program for translation regulation in cellular proliferation and          |
| 1153 | differentiation. Cell 158, 1281-1292.  |
| 1154 | Goodman, D.B., Church, G.M., and Kosuri, S. (2013). Causes and effects of N-             |
| 1155 | terminal codon bias in bacterial genes. Science 342, 475-479.                            |
| 1156 | Gradnigo, J.S., Majumdar, A., Norgren, R.B., Jr., and Moriyama, E.N. (2016).             |
| 1157 | Advantages of an Improved Rhesus Macaque Genome for Evolutionary Analyses.               |
| 1158 | PLoS One <i>11</i> , e0167376.   |
| 1159 | Gu, W., Zhou, T., and Wilke, C.O. (2010). A universal trend of reduced mRNA              |
| 1160 | stability near the translation-initiation site in prokaryotes and eukaryotes. PLoS       |
| 1161 | Comput Biol <i>6</i> , e1000664.   |
| 1162 | Higgs, D.R., Goodbourn, S.E., Lamb, J., Clegg, J.B., Weatherall, D.J., and Proudfoot,    |
| 1163 | N.J. (1983). Alpha-thalassaemia caused by a polyadenylation signal mutation.             |
| 1164 | Nature <i>306</i> , 398-400.   |
| 1165 | Kosovac, D., Wild, J., Ludwig, C., Meissner, S., Bauer, A.P., and Wagner, R. (2011).     |
| 1166 | Minimal doses of a sequence-optimized transgene mediate high-level and long-             |
| 1167 | term EPO expression in vivo: challenging CpG-free gene design. Gene Ther 18,             |
| 1168 | 189-198.   |
| 1169 | Kosuri, S., Goodman, D.B., Cambray, G., Mutalik, V.K., Gao, Y., Arkin, A.P., Endy, D.,   |
| 1170 | and Church, G.M. (2013). Composability of regulatory sequences controlling               |
| 1171 | transcription and translation in Escherichia coli. Proc Natl Acad Sci U S A 110,         |
| 1172 | 14024-14029.   |
| 1173 | Kotsopoulou, E., Kim, V.N., Kingsman, A.J., Kingsman, S.M., and Mitrophanous,            |
| 1174 | K.A. (2000). A Rev-independent human immunodeficiency virus type 1 (HIV-1)-              |
| 1175 | based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 74,             |
| 1176 | 4839-4852.   |
| 1177 | Kudla, G., Lipinski, L., Caffin, F., Helwak, A., and Zylicz, M. (2006). High guanine     |
| 1178 | and cytosine content increases mRNA levels in mammalian cells. PLoS Biol 4,              |
| 1179 | e180.  |
| 1180 | Kudla, G., Murray, A.W., Tollervey, D., and Plotkin, J.B. (2009). Coding-sequence        |
| 1181 | determinants of gene expression in Escherichia coli. Science 324, 255-258.               |

| 1100         |  |
|--------------|--|
| 1182         | Kwek, K.Y., Murphy, S., Furger, A., Thomas, B., O'Gorman, W., Kimura, H.,              |
| 1183         | Proudfoot, N.J., and Akoulitchev, A. (2002). U1 snRNA associates with TFIIH and        |
| 1184         | regulates transcriptional initiation. Nat Struct Biol 9, 800-805.                      |
| 1185         | Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon,   |
| 1186         | K., Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and          |
| 1187         | analysis of the human genome. Nature 409, 860-921.                                     |
| 1188         | Lercher, M.J., Urrutia, A.O., Pavlicek, A., and Hurst, L.D. (2003). A unification of   |
| 1189         | mosaic structures in the human genome. Hum Mol Genet <i>12</i> , 2411-2415.            |
| 1190         | Li, W. (2011). On parameters of the human genome. J Theor Biol 288, 92-104.            |
| 1191         | Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data    |
| 1192         | using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods          |
| 1192         | 25,402-408.  |
| 1193<br>1194 | Lubelsky, Y., and Ulitsky, I. (2018). Sequences enriched in Alu repeats drive          |
|              |  |
| 1195         | nuclear localization of long RNAs in human cells. Nature 555, 107-111.                 |
| 1196         | Mishima, Y., and Tomari, Y. (2016). Codon Usage and 3' UTR Length Determine            |
| 1197         | Maternal mRNA Stability in Zebrafish. Mol Cell <i>61</i> , 874-885.                    |
| 1198         | Mittal, P., Brindle, J., Stephen, J., Plotkin, J.B., and Kudla, G. (2018). Codon usage |
| 1199         | influences fitness through RNA toxicity. Proc Natl Acad Sci U S A 115, 8639-8644.      |
| 1200         | Muller-McNicoll, M., Botti, V., de Jesus Domingues, A.M., Brandl, H., Schwich, O.D.,   |
| 1201         | Steiner, M.C., Curk, T., Poser, I., Zarnack, K., and Neugebauer, K.M. (2016). SR       |
| 1202         | proteins are NXF1 adaptors that link alternative RNA processing to mRNA                |
| 1203         | export. Genes Dev <i>30</i> , 553-566.   |
| 1204         | Nott, A., Le Hir, H., and Moore, M.J. (2004). Splicing enhances translation in         |
| 1205         | mammalian cells: an additional function of the exon junction complex. Genes Dev        |
| 1206         | 18, 210-222.   |
| 1207         | Nott, A., Meislin, S.H., and Moore, M.J. (2003). A quantitative analysis of intron     |
| 1208         | effects on mammalian gene expression. RNA 9, 607-617.                                  |
| 1209         | Palazzo, A.F., and Akef, A. (2012). Nuclear export as a key arbiter of "mRNA           |
| 1210         | identity" in eukaryotes. Biochim Biophys Acta 1819, 566-577.                           |
| 1211         | Palazzo, A.F., Springer, M., Shibata, Y., Lee, C.S., Dias, A.P., and Rapoport, T.A.    |
| 1211         | (2007). The signal sequence coding region promotes nuclear export of mRNA.             |
| 1212         | PLoS Biol 5, e322.   |
| 1213         | Parmley, J.L., Urrutia, A.O., Potrzebowski, L., Kaessmann, H., and Hurst, L.D.         |
| 1214         | (2007). Splicing and the evolution of proteins in mammals. PLoS biology 5, e14.        |
| 1215         |  |
|              | Plotkin, J.B., and Kudla, G. (2011). Synonymous but not the same: the causes and       |
| 1217         | consequences of codon bias. Nat Rev Genet <i>12</i> , 32-42.                           |
| 1218         | Plotkin, J.B., Robins, H., and Levine, A.J. (2004). Tissue-specific codon usage and    |
| 1219         | the expression of human genes. Proc Natl Acad Sci U S A <i>101</i> , 12588-12591.      |
| 1220         | Ponting, C.P., and Goodstadt, L. (2009). Separating derived from ancestral             |
| 1221         | features of mouse and human genomes. Biochem Soc Trans <i>37</i> , 734-739.            |
| 1222         | Presnyak, V., Alhusaini, N., Chen, Y.H., Martin, S., Morris, N., Kline, N., Olson, S., |
| 1223         | Weinberg, D., Baker, K.E., Graveley, B.R., et al. (2015). Codon optimality is a major  |
| 1224         | determinant of mRNA stability. Cell 160, 1111-1124.                                    |
| 1225         | R Development Core Team (2005). R: A language and environment for statistical          |
| 1226         | computing (Vienna, Austria: R Foundation for Statistical Computing).                   |
| 1227         | Radhakrishnan, A., Chen, Y.H., Martin, S., Alhusaini, N., Green, R., and Coller, J.    |
| 1228         | (2016). The DEAD-Box Protein Dhh1p Couples mRNA Decay and Translation by               |
| 1229         | Monitoring Codon Optimality. Cell 167, 122-132 e129.                                   |
|              |  |

| 1230 | Ressayre, A., Glemin, S., Montalent, P., Serre-Giardi, L., Dillmann, C., and Joets, J.   |
|------|--|
| 1231 | (2015). Introns Structure Patterns of Variation in Nucleotide Composition in             |
| 1232 | Arabidopsis thaliana and Rice Protein-Coding Genes. Genome Biol Evol 7, 2913-            |
| 1233 | 2928.  |
| 1234 | Rosikiewicz, W., Kabza, M., Kosinski, J.G., Ciomborowska-Basheer, J., Kubiak, M.R.,      |
| 1235 | and Makalowska, I. (2017). RetrogeneDB-a database of plant and animal                    |
| 1236 | retrocopies. Database (Oxford) 2017.   |
| 1237 | Rudolph, K.L., Schmitt, B.M., Villar, D., White, R.J., Marioni, J.C., Kutter, C., and    |
| 1238 | Odom, D.T. (2016). Codon-Driven Translational Efficiency Is Stable across                |
| 1239 | Diverse Mammalian Cell States. PLoS Genet 12, e1006024.                                  |
| 1240 | Savisaar, R., and Hurst, L.D. (2016). Purifying Selection on Exonic Splice               |
| 1241 | Enhancers in Intronless Genes. Mol Biol Evol 33, 1396-1418.                              |
| 1242 | Semon, M., Mouchiroud, D., and Duret, L. (2005). Relationship between gene               |
| 1243 | expression and GC-content in mammals: statistical significance and biological            |
| 1244 | relevance. Hum Mol Genet 14, 421-427.  |
| 1245 | Shah, P., Ding, Y., Niemczyk, M., Kudla, G., and Plotkin, J.B. (2013). Rate-limiting     |
| 1246 | steps in yeast protein translation. Cell <i>153</i> , 1589-1601.                         |
| 1247 | Sharp, P.M., and Li, W.H. (1987a). The codon Adaptation Indexa measure of                |
| 1248 | directional synonymous codon usage bias, and its potential applications. Nucleic         |
| 1249 | Acids Res <i>15</i> , 1281-1295.   |
| 1250 | Sharp, P.M., and Li, W.H. (1987b). The rate of synonymous substitution in                |
| 1251 | enterobacterial genes is inversely related to codon usage bias. Mol Biol Evol 4,         |
| 1252 | 222-230.   |
| 1253 | Takata, M.A., Goncalves-Carneiro, D., Zang, T.M., Soll, S.J., York, A., Blanco-Melo,     |
| 1254 | D., and Bieniasz, P.D. (2017). CG dinucleotide suppression enables antiviral             |
| 1255 | defence targeting non-self RNA. Nature 550, 124-127.                                     |
| 1256 | Tuller, T., Carmi, A., Vestsigian, K., Navon, S., Dorfan, Y., Zaborske, J., Pan, T.,     |
| 1257 | Dahan, O., Furman, I., and Pilpel, Y. (2010). An evolutionarily conserved                |
| 1258 | mechanism for controlling the efficiency of protein translation. Cell 141, 344-          |
| 1259 | 354.   |
| 1260 | Vinogradov, A.E. (2003). Isochores and tissue-specificity. Nucleic Acids Res 31,         |
| 1261 | 5212-5220.   |
| 1262 | Wang, Y., Zhu, W., and Levy, D.E. (2006). Nuclear and cytoplasmic mRNA                   |
| 1263 | quantification by SYBR green based real-time RT-PCR. Methods 39, 356-362.                |
| 1264 | Webster, M.W., Chen, Y.H., Stowell, J.A.W., Alhusaini, N., Sweet, T., Graveley, B.R.,    |
| 1265 | Coller, J., and Passmore, L.A. (2018). mRNA Deadenylation Is Coupled to                  |
| 1266 | Translation Rates by the Differential Activities of Ccr4-Not Nucleases. Mol Cell         |
| 1267 | <i>70</i> , 1089-1100 e1088.   |
| 1268 | Zaghlool, A., Ameur, A., Nyberg, L., Halvardson, J., Grabherr, M., Cavelier, L., and     |
| 1269 | Feuk, L. (2013). Efficient cellular fractionation improves RNA sequencing                |
| 1270 | analysis of mature and nascent transcripts from human tissues. BMC Biotechnol            |
| 1271 | <i>13</i> , 99.  |
| 1272 | Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., |
| 1273 | Cummins, C., Gall, A., Giron, C.G., et al. (2018). Ensembl 2018. Nucleic Acids Res       |
| 1274 | <i>46</i> , D754-D761.   |
| 1275 | Zhang, L., Kasif, S., Cantor, C.R., and Broude, N.E. (2004). GC/AT-content spikes as     |
| 1276 | genomic punctuation marks. Proceedings of the National Academy of Sciences               |
| 1277 | <i>101</i> , 16855-16860.  |

| 1278 | Zhou, Z., Dang, Y., Zhou, M., Li, L., Yu, C.H., Fu, J., Chen, S., and Liu, Y. (2016). |
|------|---|
| 1279 | Codon usage is an important determinant of gene expression levels largely             |
| 1280 | through its effects on transcription. Proc Natl Acad Sci U S A 113, E6117-E6125.      |
| 1281 | Zhou, Z., Dang, Y., Zhou, M., Yuan, H., and Liu, Y. (2018). Codon usage biases co-    |
| 1282 | evolve with transcription termination machinery to suppress premature                 |
| 1283 | cleavage and polyadenylation. eLife 7.  |
| 1284 | Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J., and Muzyczka, N. (1996). A      |
| 1285 | "humanized" green fluorescent protein cDNA adapted for high-level expression          |
| 1286 | in mammalian cells. J Virol 70, 4646-4654.  |
| 1287 |   |

#### **KEY RESOURCES TABLE**

The table highlights the genetically modified organisms and strains, cell lines, reagents, software, and source data **essential** to reproduce results presented in the manuscript. Depending on the nature of the study, this may include standard laboratory materials (i.e., food chow for metabolism studies), but the Table is **not** meant to be comprehensive list of all materials and resources used (e.g., essential chemicals such as SDS, sucrose, or standard culture media don't need to be listed in the Table). **Items in the Table must also be reported in the Method Details section within the context of their use.** The number of **primers and RNA sequences** that may be listed in the Table is restricted to no more than ten each. If there are more than ten primers or RNA sequences to report, please provide this information as a supplementary document and reference this file (e.g., See Table S1 for XX) in the Key Resources Table.

*Please note that ALL references cited in the Key Resources Table must be included in the References list.* Please report the information as follows:

- **REAGENT or RESOURCE:** Provide full descriptive name of the item so that it can be identified and linked with its description in the manuscript (e.g., provide version number for software, host source for antibody, strain name). In the Experimental Models section, please include all models used in the paper and describe each line/strain as: model organism: name used for strain/line in paper: genotype. (i.e., Mouse: OXTR<sup>1//I</sup>: B6.129(SJL)-Oxtr<sup>tm1.1Wsy/J</sup>). In the Biological Samples section, please list all samples obtained from commercial sources or biological repositories. Please note that software mentioned in the Methods Details or Data and Software Availability section needs to be also included in the table. See the sample Table at the end of this document for examples of how to report reagents.
- **SOURCE:** Report the company, manufacturer, or individual that provided the item or where the item can obtained (e.g., stock center or repository). For materials distributed by Addgene, please cite the article describing the plasmid and include "Addgene" as part of the identifier. If an item is from another lab, please include the name of the principal investigator and a citation if it has been previously published. If the material is being reported for the first time in the current paper, please indicate as "this paper." For software, please provide the company name if it is commercially available or cite the paper in which it has been initially described.
- IDENTIFIER: Include catalog numbers (entered in the column as "Cat#" followed by the number, e.g., Cat#3879S). Where available, please include unique entities such as <u>RRIDs</u>, Model Organism Database numbers, accession numbers, and PDB or CAS IDs. For antibodies, if applicable and available, please also include the lot number or clone identity. For software or data resources, please include the URL where the resource can be downloaded. Please ensure accuracy of the identifiers, as they are essential for generation of hyperlinks to external sources when available. Please see the Elsevier <u>list of Data Repositories</u> with automated bidirectional linking for details. When listing more than one identifier for the same item, use semicolons to separate them (e.g. Cat#3879S; RRID: AB 2255011). If an identifier is not available, please enter "N/A" in the column.
  - A NOTE ABOUT RRIDs: We highly recommend using RRIDs as the identifier (in particular for antibodies and organisms, but also for software tools and databases). For more details on how to obtain or generate an RRID for existing or newly generated resources, please <u>visit the RII</u> or <u>search for RRIDs</u>.

Please use the empty table that follows to organize the information in the sections defined by the subheading, skipping sections not relevant to your study. Please do not add subheadings. To add a row, place the cursor at the end of the row above where you would like to add the row, just outside the right border of the table. Then press the ENTER key to add the row. Please delete empty rows. Each entry must be on a separate row; do not list multiple items in a single table cell. Please see the sample table at the end of this document for examples of how reagents should be cited.

#### TABLE FOR AUTHOR TO COMPLETE

Please upload the completed table as a separate document. <u>Please do not add subheadings to the Key</u> <u>Resources Table.</u> If you wish to make an entry that does not fall into one of the subheadings below, please contact your handling editor. (**NOTE:** For authors publishing in Current Biology, please note that references within the KRT should be in numbered style, rather than Harvard.)

#### **KEY RESOURCES TABLE**

| REAGENT or RESOURCE                           | SOURCE            | IDENTIFIER  |
|---|-------------------|-------------|
| Bacterial and Virus Strains                   |                   |             |
| DH5alpha                                      | Life Technologies | 18265017    |
| One Shot ccdB Survival 2 T1R Competent Cells  | ThermoFisher      | A10460      |
|   |                   |             |
|   |                   |             |
| Biological Samples                            |                   |             |
|   |                   |             |
|   |                   |             |
|   |                   |             |
|   |                   |             |
|   |                   |             |
| Chemicals, Peptides, and Recombinant Proteins | 1                 | 1           |
| EcoRV   | NEB               | R0195       |
| Smal  | NEB               | R0141       |
| LR Clonase II mix                             | Invitrogen        | 11791100    |
| EcoRI   | NEB               | R0101       |
| BamHI   | NEB               | R0136       |
| T4 DNA Ligase                                 | NEB               | M0202       |
| Glycoblue                                     | Invitrogen        | AM9516      |
| Phusion Taq Polymerase                        | Thermo Scientific | F530S       |
| Accuprime Pfx Polymerase                      | ThermoFisher      | 12344024    |
| RNeasy purification kit                       | Qiagen            | 74104       |
| Trizol reagent                                | Invitrogen        | 15596026    |
| Turbo DNA-free kit                            | Invitrogen        | AM1907      |
| RNAse-free DNAse kit                          | Qiagen            | 79254       |
| Opti-MEM reduced serum medium                 | Gibco             | 31985062    |
| Phenol red-free DMEM                          | Biochrom          | F0475       |
| Random hexamers                               | Promega           | C1181       |
| SuperScript III Reverse Transcriptase         | Invitrogen        | 18080044    |
| Lightcycler480 SYBR Green I Master Mix        | Roche             | 04707516001 |
| Trypan blue                                   | Sigma-Aldrich     | T8154       |
| Trypsin solution                              | Sigma-Aldrich     | T4174       |
| RNasin plus                                   | Promega           | N2611       |
| Proteinase K                                  | Roche             | 3115836001  |
| Blasticidin S                                 | Gibco             | R21001      |
| Hygromycin B                                  | Gibco             | 10687010    |
| Doxycyline                                    | Sigma-Aldrich     | D9891       |
| RNase A                                       | Qiagen            | 19101       |
| Phenol:Chlorofom:Isoamyl alcohol              | Sigma-Aldrich     | P2069       |

| Cycloheximide                          |                      |              |
|--|----------------------|--------------|
| 4-Thiouridine                          | Sigma-Aldrich        | T4509        |
| dCTP, [α-32P]- 3000Ci/mmol             | Perkin Elmer         | NEG013H250UC |
| Biotin-HPDP                            | Pierce               | 21341        |
| Dimethylformamide                      | Pierce               | 20673        |
| Triptolide                             | Sigma-Aldrich        | T3652        |
| Lipofectamine 2000                     | Invitrogen           | 11668019     |
| Critical Commercial Assays             | 5                    |              |
| Gibson Assembly Cloning Kit            | NEB                  | E5510S       |
| Qiaquick PCR purification kit          | Qiagen               | 28104        |
| MinElute PCR purification kit          | Qiagen               | 28004        |
| µMACS Streptavidin Kit                 | Miltenyi Biotec      | 130-074-101  |
| DMEM                                   | LifeTechnologies     | 41965039     |
| Trypsin EDTA solution                  | Sigma                | T4174        |
|  |                      |              |
| Deposited Data                         |                      |              |
| Sequencing data                        | SRA                  | PRJNA596086  |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
| Experimental Models: Cell Lines        |                      |              |
| HEK293 T-REx Flp-in                    | ThermoFisher         | R78007       |
| HeLa T-REx Flp-in                      | Andrew Jackson Lab,  | N/A          |
|  | MRC Human Genetics   |              |
|  | Unit, Edinburgh, UK. |              |
|  |                      |              |
|  |                      |              |
| Experimental Models: Organisms/Strains |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
| Oligonucleotides                       |                      |              |
| MiSeg library and sequencing primers   | This paper, Sigma    | Table S1     |
| Cloning primers                        | This paper, Sigma    | Table S1     |
| (q)RT-PCR primers                      | This paper, Sigma    | Table S1     |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
|  |                      |              |
| Recombinant DNA                        |                      |              |
| pGK3 (Gateway entry vector)            | Kudla et al., 2009   | N/A          |
|  |                      |              |

| GFP variants                   | Kudla et al., 2009,  | N/A           |
|--------------------------------|--|---------------|
|                                | Mittal et al., 2018  |               |
| mKate2 variants                | This paper   | N/A           |
| pCI-neo                        | Promega  | E1841         |
| pBluescript-RfA                | Grzegorz Kudla, MRC<br>Human Genetics Unit,<br>Edinburgh, UK.        | N/A           |
| pmKate2-N                      | Evrogen  | FP182         |
| pcDNA5/FRT/TO/DEST             | David Tollervey Lab,<br>University of<br>Edinburgh,Edinburgh,<br>UK. | N/A           |
| pOG44 (Flp-recombinase vector) | ThermoFisher   | V600520       |
| Software and Algorithms        |  |               |
| Python                         |  | Version 3.4.2 |
| R                              |  | Version 3.1.2 |
| FIMO                           | http://meme-suite.org  |               |
|                                |  |               |
| Other                          |  |               |
| Infinite M200 Pro plate reader | Tecan  | N/A           |
|                                |  |               |
|                                |  |               |
|                                |  |               |
|                                |  |               |

#### TABLE WITH EXAMPLES FOR AUTHOR REFERENCE

| REAGENT or RESOURCE                        | SOURCE                    | IDENTIFIER                     |
|--|---------------------------|--------------------------------|
| Antibodies                                 |                           |                                |
| Rabbit monoclonal anti-Snail               | Cell Signaling Technology | Cat#3879S; RRID:<br>AB_2255011 |
| Mouse monoclonal anti-Tubulin (clone DM1A) | Sigma-Aldrich             | Cat#T9026; RRID:<br>AB_477593  |
| Rabbit polyclonal anti-BMAL1               | This paper                | N/A                            |
| Bacterial and Virus Strains                |                           |                                |

| pAAV-hSyn-DIO-hM3D(Gq)-mCherry   | Krashes et al., 2011   | Addgene AAV5;<br>44361-AAV5                  |
|--|--|--|
| AAV5-EF1a-DIO-hChR2(H134R)-EYFP  | Hope Center Viral Vectors<br>Core  | N/A  |
| Cowpox virus Brighton Red  | BEI Resources  | NR-88  |
| Zika-SMGC-1, GENBANK: KX266255   | Isolated from patient<br>(Wang et al., 2016)   | N/A  |
| Staphylococcus aureus  | ATCC   | ATCC 29213                                   |
| <i>Streptococcus pyogenes</i> : M1 serotype strain: strain SF370; M1 GAS | ATCC   | ATCC 700294                                  |
| Biological Samples   |  |  |
| Healthy adult BA9 brain tissue   | University of Maryland<br>Brain & Tissue Bank;<br>http://medschool.umarylan<br>d.edu/btbank/ | Cat#UMB1455                                  |
| Human hippocampal brain blocks   | New York Brain Bank  | http://nybb.hs.colum<br>bia.edu/             |
| Patient-derived xenografts (PDX)   | Children's Oncology<br>Group Cell Culture and<br>Xenograft Repository                        | http://cogcell.org/                          |
| Chemicals, Peptides, and Recombinant Proteins                            | * * * *  | -  |
| MK-2206 AKT inhibitor  | Selleck Chemicals  | S1078; CAS:<br>1032350-13-2                  |
| SB-505124  | Sigma-Aldrich  | S4696; CAS:<br>694433-59-5 (free<br>base)    |
| Picrotoxin   | Sigma-Aldrich  | P1675; CAS: 124-<br>87-8                     |
| Human TGF-β  | R&D  | 240-B; GenPept:<br>P01137                    |
| Activated S6K1   | Millipore  | Cat#14-486                                   |
| GST-BMAL1  | Novus  | Cat#H00000406-<br>P01                        |
| Critical Commercial Assays   |  |  |
| EasyTag EXPRESS 35S Protein Labeling Kit                                 | Perkin-Elmer   | NEG772014MC                                  |
| CaspaseGlo 3/7   | Promega  | G8090  |
| TruSeq ChIP Sample Prep Kit  | Illumina   | IP-202-1012                                  |
| Deposited Data   |  |  |
| Raw and analyzed data  | This paper   | GEO: GSE63473                                |
| B-RAF RBD (apo) structure  | This paper   | PDB: 5J17                                    |
| Human reference genome NCBI build 37, GRCh37                             | Genome Reference<br>Consortium   | http://www.ncbi.nlm.<br>nih.gov/projects/gen |

This paper; Mendeley

This paper; and Mendeley

Data

Data

ATCC

Nanog STILT inference

Hamster: CHO cells

Experimental Models: Cell Lines

genes

Affinity-based mass spectrometry performed with 57

ome/assembly/grc/h

http://dx.doi.org/10.1

7632/wx6s4mj7s8.2

http://dx.doi.org/10.1

7632/5hvpvspw82.1

uman/


Table S8;

CRL-11268

| D. melanogaster: Cell line S2: S2-DRSC  | Laboratory of Norbert<br>Perrimon       | FlyBase:<br>FBtc0000181                          |
|---|---|--|
| Human: Passage 40 H9 ES cells   | MSKCC stem cell core<br>facility        | N/A  |
| Human: HUES 8 hESC line (NIH approval number NIHhESC-09-0021)   | HSCI iPS Core                           | hES Cell Line:<br>HUES-8                         |
| Experimental Models: Organisms/Strains  |   |  |
| <i>C. elegans</i> : Strain BC4011: srl-1(s2500) II; dpy-<br>18(e364) III; unc-46(e177)rol-3(s1040) V. | Caenorhabditis Genetics<br>Center       | WB Strain: BC4011;<br>WormBase:<br>WBVar00241916 |
| <i>D. melanogaster</i> : RNAi of Sxl: y[1] sc[*] v[1];<br>P{TRiP.HMS00609}attP2                       | Bloomington Drosophila<br>Stock Center  | BDSC:34393;<br>FlyBase:<br>FBtp0064874           |
| S. cerevisiae: Strain background: W303  | ATCC                                    | ATTC: 208353                                     |
| Mouse: R6/2: B6CBA-Tg(HDexon1)62Gpb/3J  | The Jackson Laboratory                  | JAX: 006494                                      |
| Mouse: OXTRfl/fl: B6.129(SJL)-Oxtrtm1.1Wsy/J  | The Jackson Laboratory                  | RRID:<br>IMSR_JAX:008471                         |
| Zebrafish: Tg(Shha:GFP)t10: t10Tg   | Neumann and Nuesslein-<br>Volhard, 2000 | ZFIN: ZDB-GENO-<br>060207-1                      |
| Arabidopsis: 35S::PIF4-YFP, BZR1-CFP  | Wang et al., 2012                       | N/A  |
| Arabidopsis: JYB1021.2:<br>pS24(AT5G58010)::cS24:GFP(-G):NOS #1                                       | NASC                                    | NASC ID: N70450                                  |
| Oligonucleotides  |   |  |
| siRNA targeting sequence: PIP5K I alpha #1:<br>ACACAGUACUCAGUUGAUA                                    | This paper                              | N/A  |
| Primers for XX, see Table SX  | This paper                              | N/A  |
| Primer: GFP/YFP/CFP Forward:<br>GCACGACTTCTTCAAGTCCGCCATGCC   | This paper                              | N/A  |
| Morpholino: MO-pax2a<br>GGTCTGCTTTGCAGTGAATATCCAT   | Gene Tools                              | ZFIN: ZDB-<br>MRPHLNO-061106-<br>5               |
| ACTB (hs01060665_g1)  | Life Technologies                       | Cat#4331182                                      |
| RNA sequence: hnRNPA1_ligand:<br>UAGGGACUUAGGGUUCUCUCUAGGGACUUAG<br>GGUUCUCUCUAGGGA                   | This paper                              | N/A  |
| Recombinant DNA   |   |  |
| pLVX-Tight-Puro (TetOn)   | Clonetech                               | Cat#632162                                       |
| Plasmid: GFP-Nito   | This paper                              | N/A  |
| cDNA GH111110   | Drosophila Genomics<br>Resource Center  | DGRC:5666;<br>FlyBase:FBcl013041<br>5            |
| AAV2/1-hsyn-GCaMP6- WPRE  | Chen et al., 2013                       | N/A  |
| Mouse raptor: pLKO mouse shRNA 1 raptor   | Thoreen et al., 2009                    | Addgene Plasmid<br>#21339                        |
| Software and Algorithms   |   |  |
| ImageJ  | Schneider et al., 2012                  | https://imagej.nih.go<br>v/ij/                   |

## **Cell**Press

|  |                        | 1   |
|--|------------------------|---|
| Bowtie2  | Langmead and Salzberg, | http://bowtie-  |
|  | 2012                   | bio.sourceforge.net/                                  |
|  |                        | bowtie2/index.shtml                                   |
| Samtools   | Li et al., 2009        | http://samtools.sourc                                 |
|  |                        | eforge.net/   |
| Weighted Maximal Information Component Analysis v0.9   | Rau et al., 2013       | https://github.com/C<br>hristophRau/wMICA             |
| ICS algorithm  | This paper; Mendeley   | http://dx.doi.org/10.1                                |
| 5  | Data                   | 7632/5hvpvspw82.1                                     |
| Other  | -                      | -   |
| Sequence data, analyses, and resources related to<br>the ultra-deep sequencing of the AML31 tumor,<br>relapse, and matched normal. | This paper             | http://aml31.genome<br>.wustl.edu                     |
| Resource website for the AML31 publication   | This paper             | https://github.com/ch<br>risamiller/aml31Supp<br>Site |










Figure 2





# Figure 4









Figure S1. GC variation amongst lncRNAs and parent-retrogene pairs and their downstream sequence, related to Figure 1.

**Figure S1 (continued)** (A) GC distribution of human long non-coding RNA genes, grouped by number of exons per gene. The Y axis indicates the proportion of genes within a given range of GC, calculated using the ggplot2 geom\_density() function.

(B) Mean GC content in non-coding exons, grouped by exon position (rank) and by number of exons per gene. (C) Mean GC within exons of rank 1 (black dots) or rank 2 (white dots) downstream of the transcription start site (TSS). (D) GC4 content distribution across parent and retrogene pairs conserved between human and macaque. White violins indicate pairs for which retrocopies are classed as functional (p=0.26, n=31, two-tailed Wilcoxon signed-rank test), whereas grey violins correspond to pairs in which the retrocopy is classed as non-functional pseudogene (p <  $2.2 \times 10-16$ , n=1562, two-tailed Wilcoxon signed-rank test). For the human-macaque set, the difference in GC4 between parents and functional copies is in the expected direction but not significant. (E) Violin plot showing GC content within a window between 2000 and 3000nt downstream from the stop codons of functional (grey, p< $2.2 \times 10-16$ , n=1562, two-tailed Wilcoxon signed-rank test) and non-functional grey pairs conserved between human and macaque.



**Figure S2. GC content variation amongst endogenous genes and reporter libraries, related to Figure 2.** (A) Libraries of reporter genes with random synonymous codon usage were designed to cover a broad range of GC3 content variation. Variants were expressed with and without a synthetic 5' UTR intron. (B) GC3 content distribution amongst human consensus coding sequences (CDS; grey) in comparison to the GFP variant library used in this study (GFP lib; orange). Dashed lines indicate the mean GC3 for each data set. (C-D) Loess-smoothed GC3 profiles along the 22 GFP variants (C) and 23 mKate variants (D) that were analysed by spectrofluorometry (Figure 2). (E) Sliding window analysis of GC content in 5' UTRs of intronless expression cassettes utilised in this study. Blue: pCM3 (transient transfection, no intron); red: pcDNA5/FRT/TO/DEST (stable transfection, no intron). (F) As above, intron-containing expression cassettes. Blue: pCM4 (transient transfection, with intron); red: pcDNA5/FRT/TO/DEST/INT (stable transfection, with intron). Grey shading indicates the position of the synthetic intron.







Figure S3. Effect of GC content on expression of fluorescent reporter genes in stably transfected cell lines, related to Figure 2.

**Figure S3 (continued).** (A) RT-PCR using total RNA from HEK293 Flp-In cell lines stably expressing several variants of GFP with a broad GC3 range (GC3 range: 0.3 – 0.9) and containing the same 5' UTR intron as used throughout this study. PCR was performed using either UTR-specific primers that detect spliced as well as unspliced GFP transcripts (upper gel, labelled 'UTR-specific)), or primers that exclusively detect unspliced transcripts (lower gel, labelled 'intron-specific'). Plasmids containing the respective GFP expression cassettes, both with or without UTR intron, are shown as controls. (B-C) Flow cytometry measurements of GFP variants covering a broad range of GC3 variation in stably transfected HEK293 Flp-in (B) and HeLa Flp-in (C). (D-E) qRT-PCR measurements of nascent RNA isolated using 4sU labelling from 2 GC-poor (GC3=0.3 and 0.4) and 2 GC-rich (GC3=0.88 and 0.9) GFP variants, expressed as unspliced or spliced constructs. GFP RNA levels were measured using 3' UTR specific primers (D, full length transcripts) and intronic RNA levels (E, pre-mRNA). Data points represent the mean of 2 independent experiments, -/+ SD.





(A-E) GFP Flow-Seq fluorescence scores (FS), calculated as described in the Methods section. (A) Re-sequencing of the same amplicon-library. (B-C) Replicate Flow-seq experiments performed on the same day (B) or different days (C). (D) Flow-Seq experiments performed on the same pool of cells, 24h and 48h after the induction of GFP expression. (E) Correlation between fluorescence measurements of 22 GFP variants obtained in the HeLa GFP pool cell line by Flow-Seq (X axis) and in transiently transfected HeLa cells by spectrofluorometry (Y axis, data from Figure 2).



**Figure S5. Position-specific effects of GC content on expression, related to Figures 3 and 4.** (A) Sliding window analysis of GC3 content in selected GFP variants used in the pooled amplicon sequencing experiments. (B) Correlations between the GC3 content in the 1st (nt 1-360) and 2nd (nt 361-720) halves of GFP variants and their relative cytoplasmic mRNA concentrations (RCC).




Figure S6. Distribution of RNA and protein expression data used in regression modelling, related to Figure 6.

**Figure S6 (continued)** Human RNA and protein expression data were extracted from various databases, filtered and normalized as described in Table S1 and STAR Methods. The histograms show the distributions of preprocessed expression measurements.

**Table S1. Sources of human gene expression data, related to Figure 6.** The cellular process to be quantified is indicated above the table, and the experimental techniques and data sources are indicated below. Each dot indicates an experimental replicate measurement.

|                | THAT    | Sciption nucle                   | earstability<br>orog              | ashirty and                                     | Alevels RIVA                                    | export Trat | station Prote          | n levels proteinst                | ability |
|----------------|---------|----------------------------------|-----------------------------------|---|---|-------------|------------------------|-----------------------------------|---------|
| K562           | •       |                                  |                                   | ••  | ••  |             | •                      |                                   |         |
| Gm12878        | •       |                                  |                                   | ••  | ••  |             |                        |                                   |         |
| HeLa           |         | •                                | •                                 | ••  | ••  | ••          | •                      | •                                 |         |
| Hek293         |         |                                  |                                   | ••  | ••  | ••          | •                      | •                                 |         |
| Huvec          |         |                                  |                                   | ••  | ••  |             |                        |                                   |         |
| HepG2          |         |                                  |                                   | ••  | ••  |             | •                      |                                   |         |
| A549           |         |                                  |                                   |   |   |             | •                      |                                   |         |
| GAMG           |         |                                  |                                   |   |   |             | •                      |                                   |         |
| Jurkat         |         |                                  |                                   |   |   |             | •                      |                                   |         |
| LnCap          |         |                                  |                                   |   |   |             | •                      |                                   |         |
| MCF7           |         |                                  |                                   |   |   |             | •                      |                                   |         |
| RKO            |         |                                  |                                   |   |   |             | •                      |                                   |         |
| U2OS           |         |                                  |                                   |   |   |             | •                      |                                   |         |
| data type      | GRO-cap | CAGE-seq:<br>Mtr4 KD/<br>EGFP KD | CAGE-seq:<br>Rrp40 KD/<br>Mtr4 KD | RNA-seq   | RNA-seq   | Ribo-seq    | Mass-spec              | Mass-<br>spec/Ribo-<br>seq        |         |
| data<br>source | ENCODE  | Andersson<br>et al., 2014        | Andersson<br>et al., 2014         | Hek293:<br>this study;<br>all others:<br>ENCODE | Hek293:<br>this study;<br>all others:<br>ENCODE | ENCODE      | Geiger et<br>al., 2012 | Geiger et<br>al., 2012;<br>ENCODE |         |

| Table S2. List of J  |  |
|----------------------|--|
| primer sequence      |  |
| s, related to STAR n |  |
| methods.             |  |

| Table S2. List of primer : | Table S2. List of primer sequences, related to STAR methods.                          |
|----------------------------|---|
| MiSeq library + sequencing | 5; <b>♦</b> 3;  |
| PE_PCR_left                | AATGATACGGCGACCACCGAGATCTACACGCTGGCACGCGTAAGAAGGAGATATAACCATG                         |
| S_index1_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index2_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index3_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index4_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index5_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index6_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCGCGAATTC  |
| S_index7_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| S_index8_right_PEPCR       | CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATGTGCAGGGCCCGCGAATTC |
| Read1_seq_primer_GFP       | GCTGGCACGCGTAAGAAGGAGATATAACCATG  |
| cloning primers            |   |
| pCl_del_int_F (phospho)    | GTGTCCACTCCCAGTTCAAT  |
| pCl_del_int_R (phospho)    | CTGCCCAGTGCCTCACGACC  |
| mkate2_gibs_F              | GATCCGCGTATGGTGGCCTTAAGATACATTGATGAG  |
| mkate2_gibs_R              | TGTAAGCGGATGCCGCACATGTTCTTTCCTGCG   |
| pCl_gib_F                  | CGGCATCCGCTTACAGACAA  |
| pCl_gib_R                  | CACCATACGCGGATCCTTATC   |
| qPCR primers               |   |
| pcDNA5-UTR_F               | GTTGCCAGCCATCTGTTGTT  |
| pcDNA5-UTR_R               | CTCAGACAATGCGATGCAATTTCC  |
| pc5_5UTR_F                 | CCGGGACCGATCCAGCCTCC  |
| pc5_3UTR_R1                | GCAAACAACAGATGGCTGGC  |
| pc5_3UTR_F                 | TAAGAATTCGCGGCCCTGC   |

| pc5_INT_F     | GAAGTTGGTCGTGAGGCACTG      |
|---------------|----------------------------|
| pCI-UTR_F     | CTTCCCTTTAGTGAGGGTTAATG    |
| pCI-UTR_R     | GTTTATTGCAGCTTATAATGGTTAC  |
| pCI-mRNA_F    | GCTAACGCAGTCAGTGCTTC       |
| pCI-mRNA_R    | ACACCCAGTGCCTCACGAC        |
| pCI-premRNA_F | GAGGCACTGGGCAGGTAAGTATC    |
| pCI-premRNA_R | GTGGATGTCAGTAAGACCAATAGGTG |
| Gapdh_F       | GGAGTCAACGGATTTGG          |
| Gapdh_R       | GTAGTTGAGGTCAATGAAGGG      |
| Neo_F         | CCCGTGATATTGCTGAAGAG       |
| Neo_R         | CGTCAAGAAGGCGATAGAAG       |
| LysCTT_F      | TCAGTCGGTAGAGCATGAGAC      |
| LysCTT_R      | CAACGTGGGGGCTCGAACC        |
| Malat1_F      | CAGACCCTTCACCCCTCAC        |
| Malat1_R      | TTATGGATCATGCCCACAAG       |
| cMyc_F        | CTCCTACGTTGCGGTCACAC       |
| cMyc_R        | CCGGGTCGCAGATGAAACTC       |
|               |                            |